Durvalumab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Durvalumab comprises 579 peer-reviewed publications across 15 journals, 44 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Carcinoma, Non-Small-Cell Lung, Breast Neoplasms, Carcinoma, Hepatocellular, and Lung Neoplasms. Most recent publication: Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies., Clin Cancer Res, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
    Zehir A, Benayed R, Shah RH, et al. · Nat Med · 2017
    PubMed: PMID 28481359 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  2. Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Winquist E, Hotte SJ, Chi K, et al. · Clin Cancer Res · 2025
    PubMed: PMID 39513948 · NCT02788773 · Prostatic Neoplasms
  3. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
    Seymour L, Bogaerts J, Perrone A, et al. · Lancet Oncol · 2017
    PubMed: PMID 28271869 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  4. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
    Powles T, O'Donnell PH, Massard C, et al. · JAMA Oncol · 2017
    PubMed: PMID 28817753 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  5. Bladder cancer.
    Kamat AM, Hahn NM, Efstathiou JA, et al. · Lancet · 2017
    PubMed: PMID 27345655 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  6. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
    Forde PM, Anagnostou V, Sun Z, et al. · Nat Med · 2021
    PubMed: PMID 34750557 · NCT02899195 (PrE0505) · Mesothelioma
  7. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
    Chen EX, Jonker DJ, Loree JM, et al. · JAMA Oncol · 2021
    PubMed: PMID 32379280 · NCT02870920 · Colorectal Neoplasms
  8. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    Antonia SJ, Villegas A, Daniel D, et al. · N Engl J Med · 2017
    PubMed: PMID 28885881 · NCT05000710 (CORAL-Lung) · Neoplasm Metastasis

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT02352948
ARCTIC
—Overall Survival (OS)
From randomization (Day 1) until death due to any cause, approximately 36 months
Sub-study A: Durvalumab11.7 months
Sub-study A: SoC6.8 months
Sub-study B: Durvalumab+Tremelimumab11.5 months
Sub-study B: SoC8.7 months
NCT02352948
ARCTIC
—Progression-Free Survival (PFS)
Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
Sub-study A: Durvalumab3.8 months
Sub-study A: SoC2.2 months
Sub-study B: Durvalumab+Tremelimumab3.5 months
Sub-study B: SoC3.5 months
NCT02453282
MYSTIC
Carcinoma, Non-Small-Cell LungOverall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy
From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).
Durvalumab + Tremelimumab11.9 months
Durvalumab Monotherapy16.3 months
SoC Chemotherapy12.9 months
NCT02453282
MYSTIC
Carcinoma, Non-Small-Cell LungProgression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy
Tumour scans performed at baseline then every 6 weeks up to 48 weeks relative to the date of randomization, then every 8 weeks thereafter until confirmed disease progression. Assessed up to the data cut-off date (a maximum of approximately 3 years).
Durvalumab + Tremelimumab3.9 months
SoC Chemotherapy5.4 months
NCT02516241—To Assess the Efficacy of Durvalumab + Tremelimumab Combination Therapy Versus SoC in Terms of OS in Full Analysis Set
From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Combination Therapy15.1 Months
Standard of Care12.1 Months
NCT02516241—To Assess the Efficacy of Durvalumab Monotherapy Versus SoC in Terms of OS in PD-L1-High Analysis Set
From randomization date until death due to any cause, assessed up to the data cut-off date (27JAN2020, a maximum of 5 years).
Monotherapy14.4 Months
Standard of Care12.1 Months
NCT02542293
NEPTUNE
—OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set
From baseline (Day 1, Week 0) until death due to any cause, assessed up to the China cohort DCO date (a maximum of approximately 44 months).
China: Durvalumab + Tremelimumab15.0 months
China: SoC Chemotherapy11.7 months
NCT02542293
NEPTUNE
—Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set
From baseline (Day 1, Week 0) until death due to any cause, assessed up to the Global cohort DCO date (a maximum of approximately 44 months).
Global: Durvalumab + Tremelimumab11.7 months
Global: SoC Chemotherapy9.1 months
NCT02766335—Overall Response Rate Among PD-L1 Positive Participants Treated With MEDI4736
Up to 3 years post registration
Arm I (MEDI4736 - Closed to Accrual 12/2015)14 percentage of participants
NCT02766335—Response Rate in MEDI4736-treated Participants
Up to 3 years post registration
Arm I (MEDI4736 - Closed to Accrual 12/2015)16 percentage of participants
NCT03003962—OS in Participants With LREM
From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months (DCO 27 October 2022)
Durvalumab14.6 months
Platinum-based SoC15.0 months
NCT03003962—Overall Survival (OS)
From date of randomization until death due to any cause. Assessed up to a maximum of approximately 69 months [data cut-off (DCO) 27 October 2022]
Durvalumab14.6 months
Platinum-based SoC12.8 months
NCT03043872
CASPIAN
Small Cell Lung CarcinomaOS in the China Cohort; Assessed at China Cohort First Analysis; D + EP Compared With EP
From baseline until death due to any cause. Assessed until China cohort first analysis DCO (maximum of approximately 19 months).
China Cohort: D + EP14.4 months
China Cohort: EP10.9 months
NCT03043872
CASPIAN
Small Cell Lung CarcinomaOS in the China Cohort; Assessed at China Cohort Second Analysis; D + EP Compared With EP and D + T + EP Compared With EP
From baseline until death due to any cause. Assessed until China cohort second analysis DCO (maximum of approximately 29 months).
China Cohort: D + EP14.4 months
China Cohort: D + T + EP16.1 months
China Cohort: EP10.9 months
NCT03043872
CASPIAN
Small Cell Lung CarcinomaOS in the Global Cohort; Assessed at Global Cohort Final Analysis; D + EP Compared With EP and D + T + EP Compared With EP
From baseline until death due to any cause. Assessed until global cohort final analysis DCO (maximum of approximately 33 months).
Global Cohort: D + EP12.9 months
Global Cohort: D + T + EP10.4 months
Global Cohort: EP10.5 months
NCT03043872
CASPIAN
Small Cell Lung CarcinomaOverall Survival (OS) in the Global Cohort; Assessed at Global Cohort Interim Analysis; D + EP Compared With EP
From baseline until death due to any cause. Assessed until global cohort interim analysis DCO (maximum of approximately 23 months).
Global Cohort: D + EP13.0 months
Global Cohort: EP10.3 months
NCT03084471
STRONG
Diabetes Mellitus, Insulin-Dependent, 12Number of Participants With Adverse Events of Special Interest (AESIs)
From screening to safety follow up visit (90 days after last dose), up to approximately 3 years.
AEPI300 participants
AEPI0 participants
AEPI7 participants
AEPI181 participants
AEPI119 participants
AEPI49 participants
AEPI13 participants
AEPI0 participants
AEPI145 participants
AEPI20 participants
AEPI3 participants
AESI12 participants
AESI265 participants
AESI21 participants
AESI19 participants
AESI1 participants
AESI191 participants
AESI15 participants
AESI14 participants
AESI1 participants
AESI140 participants
AESI124 participants
imAE32 participants
imAE10 participants
imAE65 participants
imAE0 participants
imAE10 participants
imAE16 participants
imAE87 participants
imAE0 participants
imAE11 participants
imAE17 participants
imAE97 participants
NCT03164616
POSEIDON
—Overall Survival (OS); D + SoC Compared With SoC Alone
From baseline until death due to any cause. Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).
D + SoC13.3 months
SoC Alone11.7 months
NCT03164616
POSEIDON
—Progression-Free Survival (PFS); D + SoC Compared With SoC Alone
Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).
D + SoC5.5 months
SoC Alone4.8 months
NCT03258554Squamous Cell Carcinoma of Head and NeckNumber of Participants With Dose-limiting Toxicity (DLT) [Lead-in Phase]
From start of durvalumab to 4 weeks after radiation therapy, approximately 13 weeks. Weekly during RT, at RT end, prior to adjuvant durvalumab, one month after end of RT.
(Lead-in) RT + Durvalumab0 Participants
NCT03258554Squamous Cell Carcinoma of Head and NeckOverall Survival (Percentage of Participants Alive) [Originally Phase III Primary / Now Phase II Secondary]
From randomization to last follow-up: weekly during RT, after end of RT: every 4 months for 1 year, every 6 months for 2 years, then annually. Additionally, every 4 weeks during adjuvant durvalumab. Maximum follow-up at time of analysis was 4.2 years.
RT + Durvalumab69.3 percentage of participants
RT+ Cetuximab77.5 percentage of participants
NCT03258554Squamous Cell Carcinoma of Head and NeckProgression-free Survival (Percentage of Participants Alive Without Progression) [Phase II Primary]
From randomization to last follow-up: weekly during RT, after end of RT: every 4 months for 1 year, every 6 months for 2 years, then annually. Additionally, every 4 weeks during adjuvant durvalumab. Maximum follow-up at time of analysis was 4.2 years.
RT + Cetuximab63.7 percentage of participants
RT + Durvalumab50.6 percentage of participants
NCT03298451
HIMALAYA
Carcinoma, HepatocellularOverall Survival (OS) - Treme 300 mg x1 Dose + Durva 1500 mg vs Sora 400 mg
From the date of randomization until death due to any cause, assessed up to the data cut-off date (27Aug2021, to a maximum of approximately 46 months).
Durva 1500 mg16.56 months
Sora 400 mg13.77 months
Treme 300 mg x1 Dose + Durva 1500 mg16.43 months
Treme 75 mg x4 Doses + Durva 1500 mg16.36 months
NCT03519971Carcinoma, Non-Small-Cell LungProgression-Free Survival (PFS)
Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).
Durvalumab + SoC CRT13.8 months
Placebo + SoC CRT9.4 months
NCT03703297
ADRIATIC
Lung NeoplasmsDurvalumab Versus Placebo: Overall Survival (OS)
From date of randomization until death due to any cause, up to DCO date 15 January 2024 (a maximum of approximately 1936 days)
Durvalumab55.9 months
Placebo33.4 months
NCT03703297
ADRIATIC
Lung NeoplasmsDurvalumab Versus Placebo: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) Per Response Evaluation Criteria in Solid Tumors Version 1.1
Response evaluations performed every 8 weeks (q8w) ± 1 week up to 72 weeks, then every 12 weeks (q12w) ± 1 week up to 96 weeks, and then every 24 weeks (q24w) thereafter until PD, up to DCO date 15 January 2024 (a maximum of approximately 1936 days)
Durvalumab16.6 months
Placebo9.2 months
NCT03706690
PACIFIC-5
Carcinoma, Non-Small-Cell LungProgression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set)
Tumor scans performed at screening, every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date 23-Jun-2024 (a maximum of approximately 2035 days)
Durvalumab14.0 months
Placebo6.5 months
NCT03732677
NIAGARA
Urinary Bladder NeoplasmsEvent-free Survival (EFS) Per Central Review Defined as Time From Randomization to Event
Up to 48 months
Durvalumab + Gemcitabine + CisplatinNA months
Gemcitabine + Cisplatin46.1 months
NCT03732677
NIAGARA
Urinary Bladder NeoplasmsPathologic Complete Response (pCR) Rates at Time of Cystectomy
Up to 6 months
Durvalumab + Gemcitabine + Cisplatin199 Participants
Gemcitabine + Cisplatin146 Participants
NCT03830866
CALLA
—Progression-free Survival (PFS) Based on the Investigator Assessment According to RECIST 1.1 or Histopathologic Confirmation of Local Tumour Progression
Tumor assessments start 20 weeks after randomisation then every 12 weeks up to 164 weeks, then every 24 weeks until date of RECIST1.1 defined radiological progression. Assessed up to date of DCO (20-Jan-2022) to a maximum of 32.6 months
Durvalumab + SoC CCRTNA Months
Placebo + SoC CCRTNA Months
NCT03875235
TOPAZ-1
Biliary Tract NeoplasmsOverall Survival (OS)
From date of randomization until death due to any cause. Assessed up to maximum of approximately 27 months (from date of randomization to primary analysis data cut-off)
Durvalumab + Gemcitabine + Cisplatin12.8 Months
Placebo + Gemcitabine + Cisplatin11.5 Months
NCT03875235
TOPAZ-1
Biliary Tract NeoplasmsOverall Survival (OS) Rate at 18 Months
From date of randomization until death due to any cause. Calculated at 18 months using the Kaplan-Meier technique.
Durvalumab + Gemcitabine + Cisplatin35.1 Percentage of Participants
Placebo + Gemcitabine + Cisplatin25.6 Percentage of Participants
NCT03875235
TOPAZ-1
Biliary Tract NeoplasmsOverall Survival (OS) Rate at 24 Months
From date of randomization until death due to any cause. Calculated at 24 months using the Kaplan-Meier technique.
Durvalumab + Gemcitabine + Cisplatin24.9 Percentage of Participants
Placebo + Gemcitabine + Cisplatin10.4 Percentage of Participants
NCT04026412
CheckMate73L
Carcinoma, Non-Small-Cell LungArm A Vs Arm C - Progression-Free Survival (PFS) by RECIST 1.1 Per Blinded Independent Central Review (BICR)
From randomization untill disease progression or death, whichever occurs first (up to approximately 53 months)
Arm A:Nivo + CCRT/Nivo + Ipi16.69 months
Arm C: CCRT/Durva15.64 months
NCT04269200
DUO-E
Endometrial NeoplasmsProgression-free Survival (PFS) According to RECIST 1.1, Based on Investigator Assessments
At baseline, every 9 weeks (wks) up to 18 wks, then every 12 wks until objective radiological disease progression. Assessed until 12 Apr 2023 DCO (08 Jul 2024 DCO for China cohort), up to 50 months
China Cohort - SoC9.7 Months
China Cohort - SoC + Durvalumab9.9 Months
China Cohort - SoC + Durvalumab + Olaparib9.9 Months
Global Cohort - SoC9.6 Months
Global Cohort - SoC + Durvalumab10.2 Months
Global Cohort - SoC + Durvalumab + Olaparib15.1 Months
NCT04385368
MERMAID-1
Carcinoma, Non-Small-Cell LungDisease-free Survival (DFS) in FAS (Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors 1.1 [RECIST 1.1])
Every 12 weeks (q12w) ± 1 week until appearance of RECIST 1.1-defined disease recurrence or until primary DFS analysis, up to 33.28 months
Durvalumab + SoCNA months
Placebo + SoCNA months
NCT04449861—Percentage of Participants With Grade ≥3 AEs
19 months
Durvalumab With EP49.7 percentage of participants
NCT04449861—Percentage of Participants With Immune-mediated Adverse Events (imAEs)
19 months
Durvalumab With EP24.2 percentage of participants
NCT04637594
IMAGINE
Carcinoma, Transitional CellOverall Survival (OS) Rate at 12 Months
12 months
Arm A (Immune Checkpoint Inhibitor)0 percentage of participants
Arm B (Immune Checkpoint Inhibitor)0 percentage of participants
NCT04642469
MERMAID-2
Carcinoma, Non-Small-Cell LungDisease-free Survival (DFS)
Every 8 weeks (q8w) ± 1 week until Week 48, then every 12 weeks (q12w) ± 1 week until appearance of RECIST 1.1-defined disease recurrence or follow-up, up to 16.6 months
Durvalumab3.9 Months
Placebo2.0 Months
NCT04712903
CANTABRICO
—Number of Patients With Adverse Events (AEs) Grade ≥ 3
During study treatment, until disease progression (median 6 months)
Experimental Arm24 Participants
Experimental Arm77 Participants
NCT04712903
CANTABRICO
—Number of Patients With Immune-mediated Adverse Events (imAE)
During study treatment, until disease progression (median 6 months)
Experimental Arm63 Participants
Experimental Arm38 Participants
NCT04774380
LUMINANCE
Small Cell Lung CarcinomaNumber of Participants With Incidence of Grade 3 or Higher Adverse Events (AEs)
From first dose of study treatment until 90 days after treatment discontinuation, up to 2.5 years.
Durvalumab+EP91 Participants
NCT04774380
LUMINANCE
Small Cell Lung CarcinomaNumber of Participants With Incidence of Immune Mediated Adverse Events (imAEs)
From first dose of study treatment until 90 days after treatment discontinuation, up to 2.5 years.
Durvalumab+EP22 Participants

Publications by year

1969–2026: 579 publications.

1969
1
1975
1
1976
1
1983
1
1985
1
1989
1
1992
2
1995
1
1996
2
1998
3
1999
2
2000
6
2001
2
2002
3
2003
3
2004
4
2005
3
2006
6
2007
6
2008
10
2009
9
2010
14
2011
11
2012
17
2013
7
2014
13
2015
20
2016
30
2017
32
2018
19
2019
24
2020
27
2021
56
2022
65
2023
39
2024
51
2025
60
2026
26

Publications by indication

Carcinoma, Non-Small-Cell Lung (171)

  • Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer.
    BMJ Oncol · 2026 · PMID 39886125 · NCT02983578
  • Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.
    Ann Oncol · 2026 · PMID 41780641 · NCT03944772
  • Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial.
    J Thorac Oncol · 2026 · PMID 41448488 · NCT04686305
  • Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.
    Nat Cancer · 2026 · PMID 42129521 · NCT04026412
  • Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.
    J Thorac Oncol · 2026 · PMID 41130408 · NCT03944772

Breast Neoplasms (56)

  • Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
    Radiol Artif Intell · 2026 · PMID 41879562 · NCT01042379
  • Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.
    Breast Cancer Res Treat · 2026 · PMID 41697438 · NCT03874325
  • Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
    J Immunother Cancer · 2026 · PMID 41881502 · NCT02484404
  • Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
    NPJ Breast Cancer · 2026 · PMID 36456573 · NCT01042379
  • Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.
    Front Oncol · 2026 · PMID 40777112 · NCT01042379

Carcinoma, Hepatocellular (49)

  • Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study.
    Nat Commun · 2026 · PMID 42151180 · NCT04945720
  • Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).
    Future Oncol · 2026 · PMID 42108643 · NCT03298451
  • Identifying Subsets of Patients with Non-immunogenic Gastrointestinal Cancers for Checkpoint Immunotherapy.
    Surg Oncol Clin N Am · 2026 · PMID 41903993 · NCT06040099
  • Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis.
    Liver Cancer · 2026 · PMID 41585428 · NCT03298451
  • Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).
    Ther Adv Med Oncol · 2026 · PMID 41732658 · NCT05844046

Lung Neoplasms (35)

  • Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.
    J Thorac Oncol · 2026 · PMID 41921748 · NCT03703297
  • Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.
    Cancer Sci · 2025 · PMID 40976711 · NCT03703297
  • Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Lancet Oncol · 2025 · PMID 39615497 · NCT05624996
  • Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
    N Engl J Med · 2024 · PMID 39268857 · NCT03703297
  • The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
    BMC Cancer · 2022 · PMID 35073853 · NCT04107168

Small Cell Lung Carcinoma (25)

  • Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study.
    Lancet Oncol · 2025 · PMID 40934933 · NCT06211036
  • Platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first-line treatment of patients with extensive-stage small-cell lung cancer: CHEST-RT (TROG 20.01) Trial - protocol for a phase II study.
    BMJ Open · 2025 · PMID 40623886 · NCT05796089
  • Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.
    Future Oncol · 2025 · PMID 40331625 · NCT03043872
  • Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
    Mol Cancer · 2024 · PMID 38811992 · NCT03043872
  • Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma.
    Cancer Med · 2023 · PMID 37489066 · NCT02658214

Urinary Bladder Neoplasms (24)

  • The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity.
    Cell Rep · 2025 · PMID 39864059 · NCT03472274
  • Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group.
    Eur Urol · 2025 · PMID 39827021 · NCT03759496
  • Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
    N Engl J Med · 2024 · PMID 39282910 · NCT03732677
  • Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
    J Clin Oncol · 2022 · PMID 35737919 · NCT03459846
  • Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial.
    Clin Genitourin Cancer · 2021 · PMID 34006499 · NCT03824691

Publications by journal

Trial-results highlights

In the MYSTIC study (NCT02453282), which investigated Non-Small-Cell Lung Carcinoma in patients with PD-L1 (TC >=25%), median Overall Survival (OS) was reported for several treatment arms. Patients receiving Durvalumab monotherapy had a median OS of 16.3 months. The Durvalumab + Tremelimumab combination arm reported a median OS of 11.9 months, while the SoC Chemotherapy arm had a median OS of 12.9 months. For Progression-Free Survival (PFS) in the same study population, the Durvalumab + Tremelimumab arm showed a median PFS of 3.9 months, and the SoC Chemotherapy arm reported a median PFS of 5.4 months. Another study, NEPTUNE (NCT02542293), included a China Cohort of PD-L1 Negative NSCLC patients, where the Durvalumab + Tremelimumab arm had a median OS of 15.0 months, compared to 11.7 months for the SoC Chemotherapy arm. The Global Cohort in NEPTUNE, focusing on patients with bTMB ≥20 Mutations Per Megabase, showed a median OS of 11.7 months for the Durvalumab + Tremelimumab arm and 9.1 months for the SoC Chemotherapy arm.

Additional studies evaluated Durvalumab in other patient populations. In the ARCTIC study (NCT02352948), Sub-study A reported a median OS of 11.7 months for the Durvalumab arm and 6.8 months for the SoC arm. Sub-study B of ARCTIC showed a median OS of 11.5 months for the Durvalumab + Tremelimumab arm and 8.7 months for the SoC arm. Regarding PFS in ARCTIC, Sub-study A's Durvalumab arm had a median PFS of 3.8 months, versus 2.2 months for the SoC arm. Sub-study B's Durvalumab + Tremelimumab arm and the SoC arm both reported a median PFS of 3.5 months. In another trial (NCT02516241), the combination therapy arm showed a median OS of 15.1 Months, compared to 12.1 Months for the Standard of Care arm. For the PD-L1-High Analysis Set in the same study, Durvalumab monotherapy had a median OS of 14.4 Months, while the Standard of Care arm had a median OS of 12.1 Months.

All values presented are sourced from primary registry reporting on ClinicalTrials.gov. For clinical decisions, individual study publications should be consulted.

All Durvalumab publications (579)

2026 (26 papers)

  1. Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies.
    Zhu X, Alvarez EA, Umetsu SE, et al. · Clin Cancer Res · 2026 · Derived
    PubMed: PMID 41686845 · NCT03682289 · Neoplasm Metastasis
  2. Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study.
    Yi J, Wang J, Zhang Y, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 42151180 · NCT04945720 · Carcinoma, Hepatocellular
  3. Plain language summary of results from the DUO-E study: durvalumab given with or without olaparib in patients with advanced endometrial cancer.
    Westin SN, Moore K, Chon HS, et al. · Future Oncol · 2026 · Derived
    PubMed: PMID 41943281 · NCT04269200 (DUO-E) · Endometrial Neoplasms
  4. Prospective evaluation of genomics-guided off-label treatment.
    Verkerk K, Spiekman AC, Haj Mohammad SF, et al. · Nature · 2026 · Derived
    PubMed: PMID 41986720 · NCT02925234 (DRUP) · Neoplasms
  5. Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.
    Thibault C, Bennamoun M, Fléchon A, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 42190158 · NCT03549715 (NEMIO)
  6. Longitudinal DCE MRI Vascular Textures: Radiologic and Biologic Insights for pCR Prediction in HER2-Negative Breast Cancer.
    Teng X, Ma J, Zhang J, et al. · Radiol Artif Intell · 2026 · Derived
    PubMed: PMID 41879562 · NCT01042379 (I-SPY) · Breast Neoplasms
  7. Preclinical study and parallel phase II trial evaluating antisense STAT3 oligonucleotide and checkpoint blockade for advanced pancreatic, non-small cell lung cancer and mismatch repair-deficient colorectal cancer.
    Tang C, Hartley GP, Couillault C, et al. · BMJ Oncol · 2026 · Derived
    PubMed: PMID 39886125 · NCT02983578 · Carcinoma, Non-Small-Cell Lung
  8. Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.
    Soyano Muller AE, Goodridge DN, Mo Q, et al. · Breast Cancer Res Treat · 2026 · Derived
    PubMed: PMID 41697438 · NCT03874325 · Breast Neoplasms
  9. Durvalumab Consolidation in Limited-Stage SCLC: Outcomes by Prior Concurrent Chemoradiotherapy and Prophylactic Cranial Irradiation in the Phase 3 ADRIATIC Trial.
    Senan S, Cho BC, Laktionov KK, et al. · J Thorac Oncol · 2026 · Derived
    PubMed: PMID 41921748 · NCT03703297 (ADRIATIC) · Lung Neoplasms
  10. Plain language summary of five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (liver cancer).
    Rimassa L, Chan SL, Sangro B, et al. · Future Oncol · 2026 · Derived
    PubMed: PMID 42108643 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  11. Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD.
    Riess JW, Yu HA, Le X, et al. · Ann Oncol · 2026 · Derived
    PubMed: PMID 41780641 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  12. Trastuzumab Deruxtecan in Patients With HER2-Overexpressing NSCLC: Results From Part 1 of the Open-Label, Multicenter, Phase 1b DESTINY-Lung03 Trial.
    Planchard D, Kim HR, Suksombooncharoen T, et al. · J Thorac Oncol · 2026 · Derived
    PubMed: PMID 41448488 · NCT04686305 (DL03) · Carcinoma, Non-Small-Cell Lung
  13. Ablatio-bilica: safety of biliary intraductal radiofrequency ablation in patients with unresectable extrahepatic biliary tract cancer undergoing systemic anti-tumor therapy: a phase II, multi-center, randomized, and controlled study.
    Pfister T, Chan SCW, Trelle S, et al. · Front Oncol · 2026 · Derived
    PubMed: PMID 41816011 · NCT06274879 (Ablatio) · Bile Duct Neoplasms
  14. Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial.
    Peters S, Tan DSW, Gerber DE, et al. · Nat Cancer · 2026 · Derived
    PubMed: PMID 42129521 · NCT04026412 (CheckMate73L) · Carcinoma, Non-Small-Cell Lung
  15. Identifying Subsets of Patients with Non-immunogenic Gastrointestinal Cancers for Checkpoint Immunotherapy.
    Pabon CM, Kumar-Sharma P, Spieler BO, et al. · Surg Oncol Clin N Am · 2026 · Derived
    PubMed: PMID 41903993 · NCT06040099 (EMERALD-Y90) · Carcinoma, Hepatocellular
  16. Phase 1 study of ceralasertib, an ATR kinase inhibitor, in combination with durvalumab in patients with recurrent or metastatic NSCLC or HNSCC.
    Lopez JS, Harrington KJ, Im SA, et al. · Br J Cancer · 2026 · Derived
    PubMed: PMID 41917211 · NCT02264678 · Ovarian Neoplasms
  17. Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer.
    Li C, Madan RA, Lee MJ, et al. · J Immunother Cancer · 2026 · Derived
    PubMed: PMID 41881502 · NCT02484404 · Breast Neoplasms
  18. Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report.
    Le X, Baik C, Cho BC, et al. · J Thorac Oncol · 2026 · Derived
    PubMed: PMID 41130408 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  19. Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer.
    Lang JE, Forero-Torres A, Yee D, et al. · NPJ Breast Cancer · 2026 · Derived
    PubMed: PMID 36456573 · NCT01042379 (I-SPY) · Breast Neoplasms
  20. CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer.
    Jackson-Spence F, Larkin J, Patel P, et al. · J Clin Oncol · 2026 · Derived
    PubMed: PMID 41861260 · NCT05043090 (SAMETA) · Neoplasm Metastasis
  21. Detection of serum HER2 in patients treated with neratinib or trastuzumab: analysis of the I-SPY Trial.
    Hensley M, Lengfeld J, Stoesz S, et al. · Front Oncol · 2026 · Derived
    PubMed: PMID 40777112 · NCT01042379 (I-SPY) · Breast Neoplasms
  22. MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer.
    Cho BC, Charoentum C, Kim DW, et al. · Lung Cancer · 2026 · Derived
    PubMed: PMID 41380462 · NCT03819465 (MAGELLAN) · Carcinoma, Non-Small-Cell Lung
  23. Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis.
    Chan SL, Kudo M, Sangro B, et al. · Liver Cancer · 2026 · Derived
    PubMed: PMID 41585428 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  24. Durvalumab plus tremelimumab for the treatment of patients with progressive, refractory advanced thyroid carcinoma: the phase II GETNE-DUTHY trial.
    Capdevila J, Hernando J, Molina-Cerillo J, et al. · Nat Commun · 2026 · Derived
    PubMed: PMID 41935063 · NCT03753919 (DUTHY) · Thyroid Neoplasms
  25. Sequential or upfront triple combination with durvalumab, tremelimumab, and bevacizumab for patients with unresectable hepatocellular carcinoma: the MONTBLANC trial protocol (AIO-HEP-0325/ass).
    Ben Khaled N, Ehmer U, Kubisch I, et al. · Ther Adv Med Oncol · 2026 · Derived
    PubMed: PMID 41732658 · NCT05844046 (MONTBLANC) · Carcinoma, Hepatocellular
  26. Sequential chemo-durvalumab, reduced dose RT, and consolidation durvalumab for unresectable stage III NSCLC unfit for PACIFIC regimen (DEDALUS trial).
    Agustoni F, Saddi J, Cortinovis DL, et al. · JNCI Cancer Spectr · 2026 · Derived
    PubMed: PMID 42093085 · NCT05128630 (DEDALUS) · Carcinoma, Non-Small-Cell Lung

2025 (60 papers)

  1. Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer.
    Winquist E, Hotte SJ, Chi K, et al. · Clin Cancer Res · 2025 · Trial result
    PubMed: PMID 39513948 · NCT02788773 · Prostatic Neoplasms
  2. Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program.
    RAINBO Research Consortium · Int J Gynecol Cancer · 2025 · Trial result
    PubMed: PMID 36600534 · NCT05255653 (RAINBO) · Endometrial Neoplasms
  3. Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallenge.
    Qin T, Mattox AK, Campbell JS, et al. · J Clin Invest · 2025 · Trial result
    PubMed: PMID 40091844 · NCT03019003 · Head and Neck Neoplasms
  4. A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer.
    Middleton G, Robbins HL, Fletcher P, et al. · NPJ Precis Oncol · 2025 · Trial result
    PubMed: PMID 40069402 · NCT02664935 · Carcinoma, Non-Small-Cell Lung
  5. Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial.
    Gupta AA, Tinker A, Jonker D, et al. · EClinicalMedicine · 2025 · Trial result
    PubMed: PMID 39737219 · NCT02879162
  6. Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.
    Zenke Y, Shiraishi Y, Goto Y, et al. · Cancer Sci · 2025 · Derived
    PubMed: PMID 40976711 · NCT03703297 (ADRIATIC) · Lung Neoplasms
  7. Biomarker-Driven Approach to the Treatment of Metastatic Gastric or Gastroesophageal Adenocarcinoma.
    Yu J, Mehta R · J Natl Compr Canc Netw · 2025 · Derived
    PubMed: PMID 40341124 · NCT04379596 (DG-03) · Esophageal Neoplasms
  8. PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy.
    Wu YL, Wu L, Bi N, et al. · J Hematol Oncol · 2025 · Derived
    PubMed: PMID 41354932 · NCT03706690 (PACIFIC-5) · Carcinoma, Non-Small-Cell Lung
  9. Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial.
    Wolf DM, Yau C, Campbell M, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 40526879 · NCT01042379 (I-SPY) · Breast Neoplasms
  10. Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma.
    Tougeron D, Louvet C, Desramé J, et al. · Commun Med (Lond) · 2025 · Derived
    PubMed: PMID 40275077 · NCT03959293 · Stomach Neoplasms
  11. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications.
    Tost J, Ak-Aksoy S, Campa D, et al. · Semin Cancer Biol · 2025 · Derived
    PubMed: PMID 39863139 · NCT03878524 · Breast Neoplasms
  12. Rationale and design for a phase IIIb trial of first-line tremelimumab plus durvalumab versus pembrolizumab, in combination with chemotherapy, in patients with non-squamous metastatic non-small-cell lung cancer and mutations or co-mutations in STK11, KEAP1, or KRAS: the TRITON study.
    Skoulidis F, Borghaei H, Garon EB, et al. · Ther Adv Med Oncol · 2025 · Derived
    PubMed: PMID 41209621 · NCT06008093 (TRITON) · Carcinoma, Non-Small-Cell Lung
  13. The spatial landscape of cancer hallmarks reveals patterns of tumor ecological dynamics and drug sensitivity.
    Sibai M, Cervilla S, Grases D, et al. · Cell Rep · 2025 · Derived
    PubMed: PMID 39864059 · NCT03472274 (DUTRENEO) · Urinary Bladder Neoplasms
  14. Prompt initiation of durvalumab and tremelimumab for unresectable hepatocellular carcinoma in patients with chronic active hepatitis B: a phase 2 clinical trial.
    Shao YY, Chen CT, Chuang CH, et al. · Br J Cancer · 2025 · Derived
    PubMed: PMID 40128285 · NCT04294498 · Carcinoma, Hepatocellular
  15. Molecular Characterization and Clinical Implications of Endometrial Cancer.
    Secord AA, Powell MA, McAlpine J, et al. · Obstet Gynecol · 2025 · Derived
    PubMed: PMID 40966692 · NCT05255653 (RAINBO) · Endometrial Neoplasms
  16. TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer.
    Schmid P, Oliveira M, O'Shaughnessy J, et al. · Ther Adv Med Oncol · 2025 · Derived
    PubMed: PMID 40297626 · NCT06103864 · Breast Neoplasms
  17. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
    Sangro B, Kudo M, Erinjeri JP, et al. · Lancet · 2025 · Derived
    PubMed: PMID 39798579 · NCT03778957 (EMERALD-1) · Carcinoma, Hepatocellular
  18. Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer.
    Rugo HS, Campbell M, Yau C, et al. · Breast Cancer Res Treat · 2025 · Derived
    PubMed: PMID 39625569 · NCT01042379 (I-SPY) · Breast Neoplasms
  19. Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.
    Rimassa L, Chan SL, Sangro B, et al. · J Hepatol · 2025 · Derived
    PubMed: PMID 40222621 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  20. ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.
    Riess JW, de Langen AJ, Ponce S, et al. · JCO Precis Oncol · 2025 · Derived
    PubMed: PMID 40466026 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  21. Phase 1 trial of durvalumab (anti-PD-L1) combined with lenalidomide in relapsed/refractory cutaneous T-cell lymphoma.
    Querfeld C, Palmer J, Han Z, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 39951620 · NCT03011814 · Lymphoma, T-Cell, Cutaneous
  22. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial.
    Peters S, Cho BC, Luft AV, et al. · J Thorac Oncol · 2025 · Derived
    PubMed: PMID 39243945 · NCT03164616 (POSEIDON)
  23. Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study.
    Paulson KG, Lau SCM, Ahn MJ, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 40934933 · NCT06211036 (DeLLphi-305) · Small Cell Lung Carcinoma
  24. Platinum and etoposide chemotherapy, durvalumab with thoracic radiotherapy in the first-line treatment of patients with extensive-stage small-cell lung cancer: CHEST-RT (TROG 20.01) Trial - protocol for a phase II study.
    Parakh S, Gee H, Lim A, et al. · BMJ Open · 2025 · Derived
    PubMed: PMID 40623886 · NCT05796089 (CHEST RT) · Small Cell Lung Carcinoma
  25. Adverse events self-reported by patients with extensive-stage small-cell lung cancer in the phase III CASPIAN study.
    Özgüroğlu M, Goldman JW, Chen Y, et al. · Future Oncol · 2025 · Derived
    PubMed: PMID 40331625 · NCT03043872 (CASPIAN) · Small Cell Lung Carcinoma
  26. Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.
    Oh DY, He AR, Qin S, et al. · J Hepatol · 2025 · Derived
    PubMed: PMID 40381735 · NCT03875235 (TOPAZ-1) · Biliary Tract Neoplasms
  27. Durvalumab plus carboplatin/paclitaxel followed by durvalumab with or without olaparib as first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: Japan subset from the phase III DUO-E trial.
    Nishio S, Nishikawa T, Mori M, et al. · J Gynecol Oncol · 2025 · Derived
    PubMed: PMID 40590327 · NCT04269200 (DUO-E) · Endometrial Neoplasms
  28. Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumab.
    Myojin Y, Babaei S, Trehan R, et al. · Gut · 2025 · Derived
    PubMed: PMID 39965889 · NCT02821754 · Carcinoma, Hepatocellular
  29. Surgical Outcomes With Neoadjuvant Durvalumab Plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC.
    Mitsudomi T, Heymach JV, Reck M, et al. · J Thorac Oncol · 2025 · Derived
    PubMed: PMID 40545237 · NCT03800134 (AEGEAN) · Carcinoma, Non-Small-Cell Lung
  30. TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2- breast cancer.
    McArthur HL, Tolaney SM, Dent R, et al. · Ther Adv Med Oncol · 2025 · Derived
    PubMed: PMID 39917260 · NCT06112379 · Breast Neoplasms
  31. Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study.
    Lu S, Wu L, Wang Q, et al. · J Thorac Oncol · 2025 · Derived
    PubMed: PMID 39521433 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  32. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
    Leon-Ferre RA, Dimitroff K, Yau C, et al. · Breast Cancer Res · 2025 · Derived
    PubMed: PMID 40551254 · NCT01042379 (I-SPY) · Breast Neoplasms
  33. Multicenter phase Ib/II study of second-line durvalumab and tremelimumab in combination with paclitaxel in patients with biomarker-selected metastatic gastric cancer.
    Lee KW, Zang DY, Kim HD, et al. · Br J Cancer · 2025 · Derived
    PubMed: PMID 40399487 · NCT03751761 · Stomach Neoplasms
  34. Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE).
    Lee CK, Liao BC, Subramaniam S, et al. · JTO Clin Res Rep · 2025 · Derived
    PubMed: PMID 39877028 · NCT03994393 (ILLUMINATE)
  35. Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
    Lau G, Abou-Alfa GK, Cheng AL, et al. · J Hepatol · 2025 · Derived
    PubMed: PMID 39089633 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  36. Evolving Therapeutics for Resectable Esophageal Adenocarcinoma.
    Klute KA, Shah MA · J Natl Compr Canc Netw · 2025 · Derived
    PubMed: PMID 40340830 · NCT04817826 (INFINITY) · Stomach Neoplasms
  37. A two-stage dual-task learning strategy for early prediction of pathological complete response to neoadjuvant chemotherapy for breast cancer using dynamic contrast-enhanced magnetic resonance images.
    Jing B, Wang J · Phys Med Biol · 2025 · Derived
    PubMed: PMID 40639409 · NCT01042379 (I-SPY) · Breast Neoplasms
  38. Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
    Janjigian YY, Al-Batran SE, Wainberg ZA, et al. · N Engl J Med · 2025 · Derived
    PubMed: PMID 40454643 · NCT04592913 · Gastrointestinal Neoplasms
  39. Durvalumab plus platinum-etoposide in the first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): A single-arm clinical trial.
    Isla D, Zugazagoitia J, Arriola E, et al. · Lung Cancer · 2025 · Derived
    PubMed: PMID 41033130 · NCT04712903 (CANTABRICO)
  40. Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-13 C]pyruvate MRI.
    Horvat-Menih I, McLean MA, Birchall J, et al. · Abdom Radiol (NY) · 2025 · Derived
    PubMed: PMID 41369900 · NCT03741426 (WIRE) · Carcinoma, Renal Cell
  41. Blood-based tumor mutational burden as a biomarker in unresectable non-small cell lung cancer treated with chemoradiotherapy and durvalumab.
    Horndalsveen H, Haakensen VD, Madebo T, et al. · Front Oncol · 2025 · Derived
    PubMed: PMID 41199847 · NCT04392505 (DART) · Carcinoma, Non-Small-Cell Lung
  42. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Heinzerling JH, Mileham KF, Robinson MM, et al. · Lancet Oncol · 2025 · Derived
    PubMed: PMID 39615497 · NCT05624996 · Lung Neoplasms
  43. T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial.
    Hawkes EA, Palmer JB, Khor R, et al. · Blood Adv · 2025 · Derived
    PubMed: PMID 40540795 · NCT03610061 (RaDD) · Lymphoma, Large B-Cell, Diffuse
  44. Combination of Olaparib, Durvalumab, and Fulvestrant in Patients with Advanced ER+/HER2- Breast Cancer and Selected Genomic Alterations: Results of the DOLAF Trial.
    Guiu S, Balmaña J, Lemercier P, et al. · Clin Cancer Res · 2025 · Derived
    PubMed: PMID 40986529 · NCT04053322 (DOLAF)
  45. Radiomics-based Machine Learning Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Using Physiologically Decomposed Diffusion-weighted MRI.
    Gilad M, Partridge SC, Iima M, et al. · Radiol Imaging Cancer · 2025 · Derived
    PubMed: PMID 40679371 · NCT01042379 (I-SPY) · Breast Neoplasms
  46. A Phase II Pilot Study of Anti-PD-L1, Durvalumab, and a PARP Inhibitor, Olaparib in Patients With Metastatic Triple-Negative Breast Cancer With or Without Germline BRCA Mutation.
    Fujii T, Cimino-Mathews A, Lipkowitz S, et al. · Cancer Med · 2025 · Derived
    PubMed: PMID 41360639 · NCT02484404 · Breast Neoplasms
  47. Intravesical Administration of Durvalumab for High-risk Non-muscle-invasive Bladder Cancer: A Phase 2 Study by the Hellenic GU Cancer Group.
    Fragkoulis C, Bamias A, Gavalas N, et al. · Eur Urol · 2025 · Derived
    PubMed: PMID 39827021 · NCT03759496 · Urinary Bladder Neoplasms
  48. A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer.
    Fitzgerald KJ, Konstantinopoulos P, Matulonis U, et al. · Gynecol Oncol · 2025 · Derived
    PubMed: PMID 40273550 · NCT03277482 · Ovarian Neoplasms
  49. Rationale and Design of the AUSTRAL trial: An Open-Label, Multicenter, Phase II Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738) in Stage III NSCLC Patients With Thoracic Relapses and/or Oligometastases After the PACIFIC Regimen.
    Filippi AR, Rulli E, Signorelli D, et al. · Clin Lung Cancer · 2025 · Derived
    PubMed: PMID 40781023 · NCT06680050 (AUSTRAL)
  50. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
    De Santis M, Palou Redorta J, Nishiyama H, et al. · Lancet · 2025 · Derived
    PubMed: PMID 41115436 · NCT03528694 (POTOMAC) · Non-Muscle Invasive Bladder Neoplasms
  51. Tremelimumab plus durvalumab combined to metronomic oral vinorelbine: Results from the breast cancer cohort of the phase II MOVIE study.
    De La Motte Rouge T, Frenel JS, Cropet C, et al. · Breast · 2025 · Derived
    PubMed: PMID 40795480 · NCT03518606 (MOVIE) · Breast Neoplasms
  52. Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients - DURVASCC trial (GOIRC-01-2021).
    Damato A, Maglietta G, Antonuzzo L, et al. · BMC Cancer · 2025 · Derived
    PubMed: PMID 41225446 · NCT06464068 (DURVASCC)
  53. 4-1BB+ Tregs and inhibitory progenitor exhausted T cells confer resistance to anti-PD-L1 and anti-CTLA-4 combination therapy.
    Cha J, Kim CG, Sim NS, et al. · Cell Rep Med · 2025 · Derived
    PubMed: PMID 41045934 · NCT03737968 · Laryngeal Diseases
  54. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.
    Cascone T, Bonanno L, Guisier F, et al. · Nat Med · 2025 · Derived
    PubMed: PMID 40450142 · NCT05061550 (NeoCOAST-2) · Carcinoma, Non-Small-Cell Lung
  55. Integrated Immune Landscape Analysis of RNA Splicing Factor-Mutant AML and Higher risk MDS Treated with Azacitidine ± Durvalumab.
    Bewersdorf JP, Hasle V, Shallis RM, et al. · Ther Adv Hematol · 2025 · Derived
    PubMed: PMID 40546817 · NCT02775903 · Myelodysplastic Syndromes
  56. Immune-mediated adverse events in the randomized phase 3 TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer.
    Antonuzzo L, Takahashi H, Park JO, et al. · Oncologist · 2025 · Derived
    PubMed: PMID 40622010 · NCT03875235 (TOPAZ-1) · Biliary Tract Neoplasms
  57. Durvalumab Alone or Combined With Novel Agents for Unresectable Stage III Non-Small Cell Lung Cancer: Update From the COAST Randomized Clinical Trial.
    Aggarwal C, Martinez-Marti A, Majem M, et al. · JAMA Netw Open · 2025 · Derived
    PubMed: PMID 40663352 · NCT03822351 (COAST) · Carcinoma, Non-Small-Cell Lung
  58. CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer.
    Walls GM, Oughton JB, Chalmers AJ, et al. · Clin Transl Radiat Oncol · 2025 · Background
    PubMed: PMID 33072895 · NCT04550104 (CONCORDE) · Carcinoma, Non-Small-Cell Lung
  59. Nuclear to Cytoplasmic Transport Is a Druggable Dependency in HDAC7-driven Small Cell Lung Cancer.
    Qin T, Wang J, Wang J, et al. · Adv Sci (Weinh) · 2025 · Background
    PubMed: PMID 39887933 · NCT07172412
  60. The UK at the Forefront of Innovative Drug-Radiotherapy Combination Clinical Trials: Introducing the CONCORDE Platform.
    Faivre-Finn C, Brown S, Ryan A, et al. · Clin Oncol (R Coll Radiol) · 2025 · Background
    PubMed: PMID 32107107 · NCT04550104 (CONCORDE) · Carcinoma, Non-Small-Cell Lung

2024 (51 papers)

  1. Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine.
    Zeidan AM, Bewersdorf JP, Hasle V, et al. · Ther Adv Hematol · 2024 · Derived
    PubMed: PMID 38883163 · NCT02775903 · Myelodysplastic Syndromes
  2. Circulating tumor DNA: from discovery to clinical application in breast cancer.
    Xu J, Gao H, Guan X, et al. · Front Immunol · 2024 · Derived
    PubMed: PMID 38745646 · NCT01042379 (I-SPY) · Breast Neoplasms
  3. Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.
    Xie M, Vuko M, Rodriguez-Canales J, et al. · Mol Cancer · 2024 · Derived
    PubMed: PMID 38811992 · NCT03043872 (CASPIAN) · Small Cell Lung Carcinoma
  4. Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
    Westin SN, Moore K, Chon HS, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 37864337 · NCT04269200 (DUO-E) · Endometrial Neoplasms
  5. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
    Voissière A, Gomez-Roca C, Chabaud S, et al. · Sci Transl Med · 2024 · Derived
    PubMed: PMID 38266104 · NCT02777710 (MEDIPLEX) · Colorectal Neoplasms
  6. FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial.
    Tougeron D, Dahan L, Evesque L, et al. · JAMA Oncol · 2024 · Derived
    PubMed: PMID 38573643 · NCT03959293 · Stomach Neoplasms
  7. Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer.
    Tan TJ, Sammons S, Im YH, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 38236575 · NCT03167619 (DORA) · Neoplasm Metastasis
  8. Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Shatsky RA, Trivedi MS, Yau C, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 39277672 · NCT01042379 (I-SPY) · Breast Neoplasms
  9. COLUMBIA-1: a randomised study of durvalumab plus oleclumab in combination with chemotherapy and bevacizumab in metastatic microsatellite-stable colorectal cancer.
    Segal NH, Tie J, Kopetz S, et al. · Br J Cancer · 2024 · Derived
    PubMed: PMID 39048638 · NCT04068610 · Colonic Neoplasms
  10. Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma.
    Sangro B, Galle PR, Kelley RK, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 38805668 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  11. NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
    Rimel BJ, Enserro D, Bender DP, et al. · Cancer · 2024 · Derived
    PubMed: PMID 38127487 · NCT03660826 · Carcinoma, Endometrioid
  12. Identification of HER2-positive breast cancer molecular subtypes with potential clinical implications in the ALTTO clinical trial.
    Rediti M, Venet D, Joaquin Garcia A, et al. · Nat Commun · 2024 · Derived
    PubMed: PMID 39613746 · NCT01042379 (I-SPY) · Breast Neoplasms
  13. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
    Powles T, Catto JWF, Galsky MD, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 39282910 · NCT03732677 (NIAGARA) · Urinary Bladder Neoplasms
  14. FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma.
    Patel TH, Brewer JR, Fan J, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 37676259 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  15. Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors.
    Patel SP, Alonso-Gordoa T, Banerjee S, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38309722 · NCT02671435 · Neoplasm Metastasis
  16. Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Park R, Li J, Slebos RJC, et al. · Oral Oncol · 2024 · Derived
    PubMed: PMID 38820888 · NCT03381183 · Squamous Cell Carcinoma of Head and Neck
  17. Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastases.
    Page DB, Beal K, Linch SN, et al. · NPJ Breast Cancer · 2024 · Derived
    PubMed: PMID 35440655 · NCT02563925 · Breast Neoplasms
  18. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
    Oh DY, Ruth He A, Qin S, et al. · NEJM Evid · 2024 · Derived
    PubMed: PMID 38319896 · NCT03875235 (TOPAZ-1) · Biliary Tract Neoplasms
  19. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study.
    Oh DY, He AR, Bouattour M, et al. · Lancet Gastroenterol Hepatol · 2024 · Derived
    PubMed: PMID 38823398 · NCT03875235 (TOPAZ-1) · Biliary Tract Neoplasms
  20. Implementation and impact of an electronic patient reported outcomes system in a phase II multi-site adaptive platform clinical trial for early-stage breast cancer.
    Northrop A, Christofferson A, Umashankar S, et al. · J Am Med Inform Assoc · 2024 · Derived
    PubMed: PMID 39158353 · NCT01042379 (I-SPY) · Breast Neoplasms
  21. Combined immune checkpoint inhibition with durvalumab and tremelimumab with and without radiofrequency ablation in patients with advanced biliary tract carcinoma.
    Monge C, Xie C, Myojin Y, et al. · Cancer Med · 2024 · Derived
    PubMed: PMID 38205877 · NCT02821754 · Carcinoma, Hepatocellular
  22. Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.
    Mell LK, Torres-Saavedra PA, Wong SJ, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 39551064 · NCT03258554 · Squamous Cell Carcinoma of Head and Neck
  23. Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial.
    Ma LX, Titmuss E, Loree JM, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39631846 · NCT02870920 · Colorectal Neoplasms
  24. Breast Multiparametric MRI for Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer: The BMMR2 Challenge.
    Li W, Partridge SC, Newitt DC, et al. · Radiol Imaging Cancer · 2024 · Derived
    PubMed: PMID 38180338 · NCT01042379 (I-SPY) · Breast Neoplasms
  25. Lung-MAP Next-Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400).
    Kozono D, Hua X, Wu MC, et al. · J Thorac Oncol · 2024 · Derived
    PubMed: PMID 39111731 · NCT02154490
  26. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
    Khoury K, Meisel JL, Yau C, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 39277671 · NCT01042379 (I-SPY) · Breast Neoplasms
  27. Identifying Indications for Neoadjuvant Therapy in Cholangiocarcinoma.
    Keller HR, Fluke L, Forrester JA, et al. · Oncology (Williston Park) · 2024 · Derived
    PubMed: PMID 38661512 · NCT03875235 (TOPAZ-1) · Biliary Tract Neoplasms
  28. Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.
    Keam B, Hong MH, Shin SH, et al. · J Clin Oncol · 2024 · Derived
    PubMed: PMID 37699162 · NCT03292250 · Squamous Cell Carcinoma of Head and Neck
  29. High-resolution and highly accelerated MRI T2 mapping as a tool to characterise renal tumour subtypes and grades.
    Horvat-Menih I, Li H, Priest AN, et al. · Eur Radiol Exp · 2024 · Derived
    PubMed: PMID 38981998 · NCT03741426 (WIRE) · Carcinoma, Renal Cell
  30. Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.
    Hirayama AV, Kimble EL, Wright JH, et al. · Blood Adv · 2024 · Derived
    PubMed: PMID 37903325 · NCT02706405 · Lymphoma, Large B-Cell, Diffuse
  31. Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
    Hinchcliff EM, Knisely A, Adjei N, et al. · Cancer · 2024 · Derived
    PubMed: PMID 38009662 · NCT03026062 · Ovarian Neoplasms
  32. Population Pharmacokinetics and Exposure-Response Analysis for the CTLA-4 Inhibitor Tremelimumab in Metastatic NSCLC Patients in the Phase III POSEIDON Study.
    He JZ, Duval V, Jauslin P, et al. · Clin Pharmacol Ther · 2024 · Derived
    PubMed: PMID 37777827 · NCT03164616 (POSEIDON)
  33. Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol.
    Geurts BS, Zeverijn LJ, Leek LVM, et al. · Clin Cancer Res · 2024 · Derived
    PubMed: PMID 38630551 · NCT02925234 (DRUP) · Neoplasms
  34. A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
    Falchook GS, Reeves J, Gandhi S, et al. · Cancer Immunol Immunother · 2024 · Derived
    PubMed: PMID 38430405 · NCT04089553 · Prostatic Neoplasms
  35. Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors.
    Davar D, Carneiro BA, Dy GK, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39551600 · NCT03889275
  36. Phase I/II study to evaluate consolidative hypofractionated radiation therapy for boosting the residual primary disease in combination with durvalumab after definitive chemoradiation therapy for stage III non-small cell lung cancer (NSCLC): study protocol for a prospective trial.
    Coutu B, Lawrence E, Ganti AK, et al. · J Thorac Dis · 2024 · Derived
    PubMed: PMID 38410608 · NCT04748419 · Carcinoma, Non-Small-Cell Lung
  37. Durvalumab plus pazopanib combination in patients with advanced soft tissue sarcomas: a phase II trial.
    Cho HJ, Yun KH, Shin SJ, et al. · Nat Commun · 2024 · Derived
    PubMed: PMID 38263321 · NCT03798106 · Sarcoma
  38. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
    Cheng Y, Spigel DR, Cho BC, et al. · N Engl J Med · 2024 · Derived
    PubMed: PMID 39268857 · NCT03703297 (ADRIATIC) · Lung Neoplasms
  39. Epithelium/imcDC2 axis facilitates the resistance of neoadjuvant anti-PD-1 in human NSCLC.
    Chen Y, Shao Z, Hao Z, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39134346 · NCT03732664
  40. Single-cell analysis reveals cellular and molecular factors counteracting HPV-positive oropharyngeal cancer immunotherapy outcomes.
    Cha J, Kim DH, Kim G, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 38857913 · NCT03737968 · Laryngeal Diseases
  41. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Burris HA, Okusaka T, Vogel A, et al. · Lancet Oncol · 2024 · Derived
    PubMed: PMID 38697156 · NCT03875235 (TOPAZ-1) · Biliary Tract Neoplasms
  42. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer.
    Bogani G, Monk BJ, Powell MA, et al. · Ann Oncol · 2024 · Derived
    PubMed: PMID 38431043 · NCT04269200 (DUO-E) · Endometrial Neoplasms
  43. Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial.
    Besse B, Pons-Tostivint E, Park K, et al. · Nat Med · 2024 · Derived
    PubMed: PMID 38351187 · NCT03334617 (HUDSON) · Carcinoma, Non-Small-Cell Lung
  44. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer.
    Barlesi F, Cho BC, Goldberg SB, et al. · Future Oncol · 2024 · Derived
    PubMed: PMID 39023287 · NCT05221840 (PACIFIC-9) · Carcinoma, Non-Small-Cell Lung
  45. TROPION-Breast03: a randomized phase III global trial of datopotamab deruxtecan ± durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy.
    Bardia A, Pusztai L, Albain K, et al. · Ther Adv Med Oncol · 2024 · Derived
    PubMed: PMID 38686016 · NCT05629585 · Breast Neoplasms
  46. Single-arm trial of neoadjuvant ipilimumab plus nivolumab with chemoradiotherapy in patients with resectable and borderline resectable lung cancer: the INCREASE study.
    Bahce I, Dickhoff C, Schneiders FL, et al. · J Immunother Cancer · 2024 · Derived
    PubMed: PMID 39349061 · NCT04245514 · Carcinoma, Non-Small-Cell Lung
  47. Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
    Altorki NK, Walsh ZH, Melms JC, et al. · Nat Commun · 2024 · Derived
    PubMed: PMID 38114518 · NCT02904954 · Carcinoma, Non-Small-Cell Lung
  48. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
    Abou-Alfa GK, Lau G, Kudo M, et al. · NEJM Evid · 2024 · Derived
    PubMed: PMID 38319892 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  49. Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT).
    Ohri N, Jolly S, Cooper BT, et al. · J Clin Oncol · 2024 · Background
    PubMed: PMID 37988638 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  50. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies.
    Liu Q, Zhang J, Guo C, et al. · Cell · 2024 · Background
    PubMed: PMID 38181741 · NCT07172412
  51. Letter: Presence of progression or absence of response? Alternative trial designs for immunotherapy of advanced hepatocellular carcinoma.
    De Toni EN, Mayerle J, Oehrle B, et al. · Aliment Pharmacol Ther · 2024 · Background
    PubMed: PMID 38643505 · NCT05844046 (MONTBLANC) · Carcinoma, Hepatocellular

2023 (39 papers)

  1. Hypofractionated Stereotactic Re-irradiation and 
Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results.
    Pouessel D, Ken S, Gouaze-Andersson V, et al. · Oncologist · 2023 · Trial result
    PubMed: PMID 37196069 · NCT02866747 (STERIMGLI) · Glioblastoma
  2. Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
    Zeverijn LJ, Looze EJ, Thavaneswaran S, et al. · Int J Cancer · 2023 · Derived
    PubMed: PMID 37424386 · NCT02925234 (DRUP) · Neoplasms
  3. Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer.
    Wu TC, Stube A, Felix C, et al. · Int J Radiat Oncol Biol Phys · 2023 · Derived
    PubMed: PMID 37023987 · NCT03148327 · Carcinoma, Non-Small-Cell Lung
  4. Sorafenib in Molecularly Selected Cancer Patients: Final Analysis of the MOST-Plus Sorafenib Cohort.
    Trédan O, Toulmonde M, Le Tourneau C, et al. · Cancers (Basel) · 2023 · Derived
    PubMed: PMID 37444551 · NCT02029001 (MOST plus) · Neoplasm Metastasis
  5. Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer.
    Topham JT, O'Callaghan CJ, Feilotter H, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36007218 · NCT02870920 · Colorectal Neoplasms
  6. First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.
    Thibaudin M, Fumet JD, Chibaudel B, et al. · Nat Med · 2023 · Derived
    PubMed: PMID 37563240 · NCT03202758 (MEDITREME) · Colorectal Neoplasms
  7. Randomized Phase 2 Placebo-Controlled Trial of Nintedanib for the Treatment of Radiation Pneumonitis.
    Rimner A, Moore ZR, Lobaugh S, et al. · Int J Radiat Oncol Biol Phys · 2023 · Derived
    PubMed: PMID 36889516 · NCT02452463 · Carcinoma, Non-Small-Cell Lung
  8. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial.
    Parker BA, Shatsky RA, Schwab RB, et al. · Breast Cancer Res Treat · 2023 · Derived
    PubMed: PMID 37029329 · NCT01042379 (I-SPY) · Breast Neoplasms
  9. Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D.
    Park J, Lee JB, Lim MC, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 37865397 · NCT03899610 (KGOG3046) · Ovarian Neoplasms
  10. Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
    Onishi N, Bareng TJ, Gibbs J, et al. · Radiol Imaging Cancer · 2023 · Derived
    PubMed: PMID 37505107 · NCT01042379 (I-SPY) · Breast Neoplasms
  11. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
    Mukhtar RA, Chau H, Woriax H, et al. · Ann Surg · 2023 · Derived
    PubMed: PMID 37325931 · NCT01042379 (I-SPY) · Breast Neoplasms
  12. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial.
    Monk BJ, Toita T, Wu X, et al. · Lancet Oncol · 2023 · Derived
    PubMed: PMID 38039991 · NCT03830866 (CALLA)
  13. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
    Monge C, Xie C, Myojin Y, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 36754451 · NCT03206073 · Colorectal Neoplasms
  14. A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study.
    Mamdani H, Schneider B, Perkins SM, et al. · Front Oncol · 2023 · Derived
    PubMed: PMID 34604072 · NCT02639065 · Esophageal Neoplasms
  15. A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE).
    Mahmood S, Li D, Lee A, et al. · Future Oncol · 2023 · Derived
    PubMed: PMID 36912078 · NCT03970616 (DEDUCTIVE) · Carcinoma, Hepatocellular
  16. Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma.
    Lee DH, Kim HR, Keam B, et al. · Cancer Med · 2023 · Derived
    PubMed: PMID 37489066 · NCT02658214 · Small Cell Lung Carcinoma
  17. Factors associated with failure to start consolidation durvalumab after definitive chemoradiation for locally advanced NSCLC.
    Langberg CW, Horndalsveen H, Helland Å, et al. · Front Oncol · 2023 · Derived
    PubMed: PMID 37476372 · NCT04392505 (DART) · Carcinoma, Non-Small-Cell Lung
  18. Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023.
    Joshi M, Tuanquin L, Zhu J, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 36822667 · NCT02891161 (DUART)
  19. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study.
    Johnson ML, Cho BC, Luft A, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 36327426 · NCT03164616 (POSEIDON)
  20. Population Pharmacokinetics of Monalizumab in Patients With Advanced Solid Tumors.
    Hwang M, Fan C, Yue MS, et al. · J Clin Pharmacol · 2023 · Derived
    PubMed: PMID 36852723 · NCT02671435 · Neoplasm Metastasis
  21. Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
    Heymach JV, Harpole D, Mitsudomi T, et al. · N Engl J Med · 2023 · Derived
    PubMed: PMID 37870974 · NCT03800134 (AEGEAN) · Carcinoma, Non-Small-Cell Lung
  22. Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the PANDORA trial.
    Grassi E, Zingaretti C, Petracci E, et al. · ESMO Open · 2023 · Derived
    PubMed: PMID 37774508 · NCT04083365 (PANDORA) · Rectal Neoplasms
  23. Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
    Geurts BS, Battaglia TW, van Berge Henegouwen JM, et al. · BMC Cancer · 2023 · Derived
    PubMed: PMID 36870947 · NCT02925234 (DRUP) · Neoplasms
  24. Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial.
    Gallagher RI, Wulfkuhle J, Wolf DM, et al. · Cell Rep Med · 2023 · Derived
    PubMed: PMID 38086377 · NCT01042379 (I-SPY) · Breast Neoplasms
  25. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
    Gaitskell K, Rogozińska E, Platt S, et al. · Cochrane Database Syst Rev · 2023 · Derived
    PubMed: PMID 37185961 · NCT03737643 (DUO-O) · Ovarian Neoplasms
  26. Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.
    Fumet JD, Isambert N, Hervieu A, et al. · ESMO Open · 2023 · Derived
    PubMed: PMID 29942666 · NCT03202758 (MEDITREME) · Colorectal Neoplasms
  27. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Di Dio C, Bogani G, Di Donato V, et al. · Gynecol Oncol · 2023 · Derived
    PubMed: PMID 36493574 · NCT03015129 · Recurrence
  28. First-in-human study of SBRT and adenosine pathway blockade to potentiate the benefit of immunochemotherapy in early-stage luminal B breast cancer: results of the safety run-in phase of the Neo-CheckRay trial.
    De Caluwe A, Romano E, Poortmans P, et al. · J Immunother Cancer · 2023 · Derived
    PubMed: PMID 38056900 · NCT03875573 (Neo-CheckRay) · Breast Neoplasms
  29. CD8+ and FoxP3+ T-Cell Cellular Density and Spatial Distribution After Programmed Death-Ligand 1 Check Point Inhibition.
    Curry J, Alnemri A, Philips R, et al. · Laryngoscope · 2023 · Derived
    PubMed: PMID 36125263 · NCT03618654 · Squamous Cell Carcinoma of Head and Neck
  30. NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer.
    Cheng Y, Zhou Q, Han B, et al. · Lung Cancer · 2023 · Derived
    PubMed: PMID 36806898 · NCT02542293 (NEPTUNE)
  31. Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial.
    Casulo C, Santoro A, Cartron G, et al. · Cancer Rep (Hoboken) · 2023 · Derived
    PubMed: PMID 35852004 · NCT02733042 (FUSION NHL 001) · Lymphoma, Large B-Cell, Diffuse
  32. Neoadjuvant Durvalumab Alone or Combined with Novel Immuno-Oncology Agents in Resectable Lung Cancer: The Phase II NeoCOAST Platform Trial.
    Cascone T, Kar G, Spicer JD, et al. · Cancer Discov · 2023 · Derived
    PubMed: PMID 37707791 · NCT03794544 · Carcinoma, Non-Small-Cell Lung
  33. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.
    Capdevila J, Hernando J, Teule A, et al. · Nat Commun · 2023 · Derived
    PubMed: PMID 37221181 · NCT03095274 (DUNE) · Neuroendocrine Tumors
  34. Anti PD-L1 DUrvalumab combined with Cetuximab and RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A phase I/II study (DUCRO).
    Bonomo P, Desideri I, Loi M, et al. · Clin Transl Radiat Oncol · 2023 · Derived
    PubMed: PMID 29594250 · NCT03051906 (DUCRO-HN) · Head and Neck Neoplasms
  35. First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors.
    Bendell J, LoRusso P, Overman M, et al. · Cancer Immunol Immunother · 2023 · Derived
    PubMed: PMID 37016126 · NCT02503774 · Carcinoma, Non-Small-Cell Lung
  36. Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study.
    Ahn MJ, Bondarenko I, Kalinka E, et al. · J Thorac Oncol · 2023 · Derived
    PubMed: PMID 37390980 · NCT03775486 (ORION)
  37. Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma.
    J Immunother Cancer · 2023 · Derived
    PubMed: PMID 37678916 · NCT03298451 (HIMALAYA) · Carcinoma, Hepatocellular
  38. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data.
    Rimini M, Fornaro L, Lonardi S, et al. · Liver Int · 2023 · Background
    PubMed: PMID 37452505 · NCT06274879 (Ablatio) · Bile Duct Neoplasms
  39. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Kelley RK, Ueno M, Yoo C, et al. · Lancet · 2023 · Background
    PubMed: PMID 37075781 · NCT06274879 (Ablatio) · Bile Duct Neoplasms

2022 (65 papers)

  1. The CCTG PA.7 phase II trial of gemcitabine and nab-paclitaxel with or without durvalumab and tremelimumab as initial therapy in metastatic pancreatic ductal adenocarcinoma.
    Renouf DJ, Loree JM, Knox JJ, et al. · Nat Commun · 2022 · Trial result
    PubMed: PMID 36028483 · NCT02879318
  2. CCTG BR34: A Randomized Phase 2 Trial of Durvalumab and Tremelimumab With or Without Platinum-Based Chemotherapy in Patients With Metastatic NSCLC.
    Leighl NB, Laurie SA, Goss GD, et al. · J Thorac Oncol · 2022 · Trial result
    PubMed: PMID 34800700 · NCT03057106
  3. Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial.
    Italiano A, Dinart D, Soubeyran I, et al. · BMC Cancer · 2022 · Trial result
    PubMed: PMID 34740331 · NCT03784014 (MULTISARC) · Neoplasm Metastasis
  4. Hypofractionated Irradiation Has Immune Stimulatory Potential and Induces a Timely Restricted Infiltration of Immune Cells in Colon Cancer Tumors.
    Frey B, Rückert M, Weber J, et al. · Front Immunol · 2022 · Trial result
    PubMed: PMID 28337197 · NCT05000710 (CORAL-Lung) · Neoplasm Metastasis
  5. Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma.
    Canova S, Ceresoli GL, Grosso F, et al. · ESMO Open · 2022 · Trial result
    PubMed: PMID 36463732 · NCT04115111 (Diadem) · Mesothelioma, Malignant
  6. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes.
    Zeidan AM, Boss I, Beach CL, et al. · Blood Adv · 2022 · Derived
    PubMed: PMID 34972214 · NCT02775903 · Myelodysplastic Syndromes
  7. A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML.
    Zeidan AM, Boss I, Beach CL, et al. · Blood Adv · 2022 · Derived
    PubMed: PMID 34933333 · NCT02775903 · Myelodysplastic Syndromes
  8. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).
    Yu HA, Goldberg SB, Le X, et al. · Clin Lung Cancer · 2022 · Derived
    PubMed: PMID 34389237 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  9. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies.
    Wolf DM, Yau C, Wulfkuhle J, et al. · Cancer Cell · 2022 · Derived
    PubMed: PMID 35623341 · NCT01042379 (I-SPY) · Breast Neoplasms
  10. Neoadjuvant durvalumab for resectable non-small-cell lung cancer (NSCLC): results from a multicenter study (IFCT-1601 IONESCO).
    Wislez M, Mazieres J, Lavole A, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 36270733 · NCT03030131 (IONESCO) · Carcinoma, Non-Small-Cell Lung
  11. Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations-CONCORDE.
    Walker K, Hinsley S, Phillip R, et al. · JCO Precis Oncol · 2022 · Derived
    PubMed: PMID 36446040 · NCT04550104 (CONCORDE) · Carcinoma, Non-Small-Cell Lung
  12. A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma.
    Voss MH, Azad AA, Hansen AR, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35507017 · NCT02118337 · Carcinoma, Renal Cell
  13. Efficacy and toxicity of vemurafenib and cobimetinib in relation to plasma concentrations, after administration via feeding tube in patients with BRAF-mutated thyroid cancer: a case series and review of literature.
    van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, et al. · Cancer Chemother Pharmacol · 2022 · Derived
    PubMed: PMID 35598186 · NCT02925234 (DRUP) · Neoplasms
  14. The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer - a study protocol.
    Ursprung S, Mossop H, Gallagher FA, et al. · BMC Cancer · 2022 · Derived
    PubMed: PMID 34794412 · NCT03741426 (WIRE) · Carcinoma, Renal Cell
  15. Postneoadjuvant treatment for triple-negative breast cancer.
    Trapani D, Ferraro E, Giugliano F, et al. · Curr Opin Oncol · 2022 · Derived
    PubMed: PMID 35993306 · NCT01042379 (I-SPY) · Breast Neoplasms
  16. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
    Thompson NA, Stewart GD, Welsh SJ, et al. · BMC Cancer · 2022 · Derived
    PubMed: PMID 35073853 · NCT04107168 · Lung Neoplasms
  17. Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
    Symmans WF, Yau C, Chen YY, et al. · JAMA Oncol · 2022 · Derived
    PubMed: PMID 34529000 · NCT01042379 (I-SPY) · Breast Neoplasms
  18. Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment.
    Subudhi SK, Siddiqui BA, Aparicio AM, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34663638 · NCT03204812 · Prostatic Neoplasms
  19. We need to bring R0 < 1 to treat cancer too.
    Srikrishna D, Sachsenmeier K · Genome Med · 2022 · Derived
    PubMed: PMID 34311780 · NCT03739931 · Squamous Cell Carcinoma of Head and Neck
  20. Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma.
    Sonpavde GP, Sternberg CN, Loriot Y, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 35042068 · NCT03084471 (STRONG) · Diabetes Mellitus, Insulin-Dependent, 12
  21. Durvalumab plus tremelimumab in advanced or metastatic soft tissue and bone sarcomas: a single-centre phase 2 trial.
    Somaiah N, Conley AP, Parra ER, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35934010 · NCT02815995 · Hemangiosarcoma
  22. DNA Damage Repair Inhibitors-Combination Therapies.
    Smith G, Alholm Z, Coleman RL, et al. · Cancer J · 2022 · Derived
    PubMed: PMID 34904813 · NCT02264678 · Ovarian Neoplasms
  23. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.
    Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S, et al. · Lancet Oncol · 2022 · Derived
    PubMed: PMID 35033226 · NCT02888743 · Carcinoma, Non-Small-Cell Lung
  24. Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
    Rosenberg JE, Park SH, Kozlov V, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35737919 · NCT03459846 (BAYOU) · Urinary Bladder Neoplasms
  25. Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer.
    Revenko A, Carnevalli LS, Sinclair C, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 35387780 · NCT04504669 · Carcinoma, Non-Small-Cell Lung
  26. Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer.
    Park S, Noh JM, Choi YL, et al. · Eur J Cancer · 2022 · Derived
    PubMed: PMID 35500460 · NCT03585998 · Small Cell Lung Carcinoma
  27. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    Osdoit M, Yau C, Symmans WF, et al. · JAMA Surg · 2022 · Derived
    PubMed: PMID 36069821 · NCT01042379 (I-SPY) · Breast Neoplasms
  28. Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
    Oh DY, Lee KH, Lee DW, et al. · Lancet Gastroenterol Hepatol · 2022 · Derived
    PubMed: PMID 35278356 · NCT03046862 · Biliary Tract Neoplasms
  29. Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study.
    Nishina T, Fujita T, Yoshizuka N, et al. · BMJ Open · 2022 · Derived
    PubMed: PMID 36270753 · NCT03394144
  30. Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma.
    Nakauma-González JA, Rijnders M, van Riet J, et al. · Eur Urol · 2022 · Derived
    PubMed: PMID 35086719 · NCT02925234 (DRUP) · Neoplasms
  31. How patients being treated for non-small cell lung cancer value treatment benefit despite side effects.
    Martin ML, Correll J, Walding A, et al. · Qual Life Res · 2022 · Derived
    PubMed: PMID 34056687 · NCT02352948 (ARCTIC)
  32. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers.
    Maia MC, Salgia M, Pal SK, et al. · Nat Rev Urol · 2022 · Derived
    PubMed: PMID 32203306 · NCT03385655 · Prostatic Neoplasms
  33. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
    Leighl NB, Redman MW, Rizvi N, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 34429332 · NCT03373760
  34. A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer.
    Lee NY, Riaz N, Wu V, et al. · Thyroid · 2022 · Derived
    PubMed: PMID 35521657 · NCT03122496 · Thyroid Carcinoma, Anaplastic
  35. Biomarker-guided targeted therapy in platinum-resistant ovarian cancer (AMBITION; KGOG 3045): a multicentre, open-label, five-arm, uncontrolled, umbrella trial.
    Lee JY, Kim BG, Kim JW, et al. · J Gynecol Oncol · 2022 · Derived
    PubMed: PMID 35320892 · NCT03699449
  36. Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in non-small cell lung cancer: Results from a randomized trial.
    Lee B, Mynard N, Nasar A, et al. · J Thorac Cardiovasc Surg · 2022 · Derived
    PubMed: PMID 36028357 · NCT02904954 · Carcinoma, Non-Small-Cell Lung
  37. Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer.
    Kwon M, Kim G, Kim R, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 35790315 · NCT03780608 · Melanoma
  38. Local and Regional Therapies for Hepatocellular Carcinoma.
    Kloeckner R, Galle PR, Bruix J, et al. · Hepatology · 2022 · Derived
    PubMed: PMID 32557715 · NCT03778957 (EMERALD-1) · Carcinoma, Hepatocellular
  39. Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC).
    Johnson B, Haymaker CL, Parra ER, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 36007963 · NCT03428126 · Colorectal Neoplasms
  40. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.
    Janjigian YY, Van Cutsem E, Muro K, et al. · Future Oncol · 2022 · Derived
    PubMed: PMID 35535555 · NCT04592913 · Gastrointestinal Neoplasms
  41. Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer.
    Jabbour SK, Cho BC, Bria E, et al. · Clin Lung Cancer · 2022 · Derived
    PubMed: PMID 35618629 · NCT04380636 · Carcinoma, Non-Small-Cell Lung
  42. Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer.
    Huang Y, Zhao JJ, Soon YY, et al. · Thorac Cancer · 2022 · Derived
    PubMed: PMID 36177913 · NCT03840902 · Carcinoma, Non-Small-Cell Lung
  43. COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
    Herbst RS, Majem M, Barlesi F, et al. · J Clin Oncol · 2022 · Derived
    PubMed: PMID 35452273 · NCT03822351 (COAST) · Carcinoma, Non-Small-Cell Lung
  44. Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer.
    Hecht M, Eckstein M, Rutzner S, et al. · J Immunother Cancer · 2022 · Derived
    PubMed: PMID 35078923 · NCT03426657
  45. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).
    Hanna CR, O'Cathail SM, Graham JS, et al. · Radiat Oncol · 2022 · Derived
    PubMed: PMID 34446053 · NCT04621370 (PRIME-RT) · Rectal Neoplasms
  46. Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
    Goldman JW, Piha-Paul SA, Curti B, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35699623 · NCT02705482 · Neoplasms
  47. Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC).
    Garon EB, Cho BC, Reinmuth N, et al. · Clin Lung Cancer · 2022 · Derived
    PubMed: PMID 33775558 · NCT02453282 (MYSTIC) · Carcinoma, Non-Small-Cell Lung
  48. Durvalumab After Sequential Chemoradiotherapy in Stage III, Unresectable NSCLC: The Phase 2 PACIFIC-6 Trial.
    Garassino MC, Mazieres J, Reck M, et al. · J Thorac Oncol · 2022 · Derived
    PubMed: PMID 35961520 · NCT03693300 · Carcinoma, Non-Small-Cell Lung
  49. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
    Filippi AR, Dziadziuszko R, García Campelo MR, et al. · Future Oncol · 2022 · Derived
    PubMed: PMID 34775804 · NCT04249362 (DUART) · Carcinoma, Non-Small-Cell Lung
  50. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
    Falchook GS, Peeters M, Rottey S, et al. · Invest New Drugs · 2022 · Derived
    PubMed: PMID 33852104 · NCT02718911
  51. CheckMate 73L: A Phase 3 Study Comparing Nivolumab Plus Concurrent Chemoradiotherapy Followed by Nivolumab With or Without Ipilimumab Versus Concurrent Chemoradiotherapy Followed by Durvalumab for Previously Untreated, Locally Advanced Stage III Non-Small-Cell Lung Cancer.
    De Ruysscher D, Ramalingam S, Urbanic J, et al. · Clin Lung Cancer · 2022 · Derived
    PubMed: PMID 34489161 · NCT04026412 (CheckMate73L) · Carcinoma, Non-Small-Cell Lung
  52. A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC.
    Darragh LB, Knitz MM, Hu J, et al. · Nat Cancer · 2022 · Derived
    PubMed: PMID 36434392 · NCT03635164 · Squamous Cell Carcinoma of Head and Neck
  53. Top advances in esophageal/gastroesophageal junction cancers in 2021.
    Cowzer D, Janjigian YY · Cancer · 2022 · Derived
    PubMed: PMID 35179774 · NCT04592913 · Gastrointestinal Neoplasms
  54. The current management and biomarkers of immunotherapy in advanced gastric cancer.
    Chang X, Ge X, Zhang Y, et al. · Medicine (Baltimore) · 2022 · Derived
    PubMed: PMID 35623069 · NCT04592913 · Gastrointestinal Neoplasms
  55. Preliminary report on harmonization of features extraction process using the ComBat tool in the multi-center "Blue Sky Radiomics" study on stage III unresectable NSCLC.
    Cabini RF, Brero F, Lancia A, et al. · Insights Imaging · 2022 · Derived
    PubMed: PMID 35254525 · NCT04364776 · Lung Neoplasms
  56. Durvalumab with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of the head and neck: A phase 1/2 trial.
    Bonomo P, Desideri I, Mangoni M, et al. · Radiother Oncol · 2022 · Derived
    PubMed: PMID 35157978 · NCT03051906 (DUCRO-HN) · Head and Neck Neoplasms
  57. F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial.
    Beck M, Hartwich J, Eckstein M, et al. · Ann Nucl Med · 2022 · Derived
    PubMed: PMID 35534690 · NCT03426657
  58. Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Valle JW, Borbath I, Khan SA, et al. · Ann Oncol · 2022 · Background
    PubMed: PMID 27664259 · NCT04308174 (DEBATE) · Biliary Tract Neoplasms
  59. Radiotherapy for locally advanced unresectable gallbladder cancer - A way forward: Comparative study of chemotherapy versus chemoradiotherapy.
    Sinha S, Engineer R, Ostwal V, et al. · J Cancer Res Ther · 2022 · Background
    PubMed: PMID 35381776 · NCT06214572 (RUGB) · Biliary Tract Neoplasms
  60. Effects of conventional therapeutic interventions on the number and function of regulatory T cells.
    Roselli M, Cereda V, di Bari MG, et al. · Oncoimmunology · 2022 · Background
    PubMed: PMID 24353914 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  61. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.
    Paz-Ares L, Chen Y, Reinmuth N, et al. · ESMO Open · 2022 · Background
    PubMed: PMID 35279527 · NCT05683977 (ARSENAL) · Small Cell Lung Carcinoma
  62. Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial.
    Kok PS, Forde PM, Hughes B, et al. · BMJ Open · 2022 · Background
    PubMed: PMID 35078853 · NCT04334759 (DREAM3R) · Mesothelioma
  63. Elective nodal irradiation mitigates local and systemic immunity generated by combination radiation and immunotherapy in head and neck tumors.
    Darragh LB, Gadwa J, Pham TT, et al. · Nat Commun · 2022 · Background
    PubMed: PMID 36385142 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  64. A Real-World, Multicenter, Observational Retrospective Study of Durvalumab After Concomitant or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer.
    Bruni A, Scotti V, Borghetti P, et al. · Front Oncol · 2022 · Background
    PubMed: PMID 34650927 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  65. Nationwide Real-Life Safety and Treatment Exposure Data on Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III, Locally Advanced, Non-small Cell Lung Cancer: Analysis of Patients Enrolled in the French Early Access Program.
    Avrillon V, Daniel C, Boisselier P, et al. · Lung · 2022 · Background
    PubMed: PMID 35141799 · NCT05683977 (ARSENAL) · Small Cell Lung Carcinoma

2021 (56 papers)

  1. A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.
    Juergens RA, Hao D, Ellis PM, et al. · Lung Cancer · 2021 · Trial result
    PubMed: PMID 32169783 · NCT02537418
  2. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
    Forde PM, Anagnostou V, Sun Z, et al. · Nat Med · 2021 · Trial result
    PubMed: PMID 34750557 · NCT02899195 (PrE0505) · Mesothelioma
  3. Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan.
    FGM 2025 Workflow Study Group (Alliance nationale des Sciences de la Vie et de la Santé), Auzanneau C, Bacq D, et al. · ESMO Open · 2021 · Trial result
    PubMed: PMID 32713836 · NCT03784014 (MULTISARC) · Neoplasm Metastasis
  4. A Phase II Study of Durvalumab in Combination with Tremelimumab in Patients with Rare Cancers.
    Edenfield WJ, Chung K, O'Rourke M, et al. · Oncologist · 2021 · Trial result
    PubMed: PMID 33893692 · NCT02938793 · Neoplasms
  5. Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
    Chen EX, Jonker DJ, Loree JM, et al. · JAMA Oncol · 2021 · Trial result
    PubMed: PMID 32379280 · NCT02870920 · Colorectal Neoplasms
  6. Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study.
    Zamarin D, Hamid O, Nayak-Kapoor A, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 32586937 · NCT02301130
  7. Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma.
    Young MH, Pietz G, Whalen E, et al. · Sci Rep · 2021 · Derived
    PubMed: PMID 34385543 · NCT02616640 · Recurrence
  8. CheckMate 743: A Glimmer of Hope for Malignant Pleural Mesothelioma.
    Uprety D · Clin Lung Cancer · 2021 · Derived
    PubMed: PMID 33358660 · NCT04334759 (DREAM3R) · Mesothelioma
  9. An open-label, phase II multicohort study of an oral hypomethylating agent CC-486 and durvalumab in advanced solid tumors.
    Taylor K, Loo Yau H, Chakravarthy A, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 32753546 · NCT02811497 (METADUR)
  10. Systems approach to rational combination therapy: PARP inhibitors.
    Sun C, Fang Y, Labrie M, et al. · Biochem Soc Trans · 2021 · Derived
    PubMed: PMID 32379297 · NCT03801369 · Triple Negative Breast Neoplasms
  11. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.
    Siu L, Brody J, Gupta S, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 33037117 · NCT02556463 · Neoplasms
  12. Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.
    Senan S, Okamoto I, Lee GW, et al. · Clin Lung Cancer · 2021 · Derived
    PubMed: PMID 31948903 · NCT03703297 (ADRIATIC) · Lung Neoplasms
  13. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
    Rizvi NA, Cho BC, Reinmuth N, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32271377 · NCT02453282 (MYSTIC) · Carcinoma, Non-Small-Cell Lung
  14. Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP SWOG S1400): a biomarker-driven master protocol.
    Redman MW, Papadimitrakopoulou VA, Minichiello K, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 33125909 · NCT02154490
  15. Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
    Quintela-Fandino M, Holgado E, Manso L, et al. · Breast Cancer Res · 2021 · Derived
    PubMed: PMID 33176887 · NCT02802098 · Breast Neoplasms
  16. The DNA damage response network in the treatment of head and neck squamous cell carcinoma.
    Psyrri A, Gkotzamanidou M, Papaxoinis G, et al. · ESMO Open · 2021 · Derived
    PubMed: PMID 33714009 · NCT02882308 (OPHELIA) · Squamous Cell Carcinoma of Head and Neck
  17. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.
    Powles T, van der Heijden MS, Castellano D, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 32971005 · NCT02516241
  18. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer.
    Planchard D, Reinmuth N, Orlov S, et al. · Ann Oncol · 2021 · Derived
    PubMed: PMID 32201234 · NCT02352948 (ARCTIC)
  19. Atezolizumab in the treatment of metastatic triple-negative breast cancer.
    Pérez-García J, Soberino J, Racca F, et al. · Expert Opin Biol Ther · 2021 · Derived
    PubMed: PMID 32450725 · NCT01042379 (I-SPY) · Breast Neoplasms
  20. Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study.
    Pakkala S, Higgins K, Chen Z, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 33428583 · NCT02701400 · Small Cell Lung Carcinoma
  21. RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapse.
    Oza B, Frangou E, Smith B, et al. · Contemp Clin Trials · 2021 · Derived
    PubMed: PMID 34538402 · NCT03288532 (RAMPART) · Carcinoma, Renal Cell
  22. A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).
    Ngoi NY, Heong V, Ow S, et al. · Int J Gynecol Cancer · 2021 · Derived
    PubMed: PMID 32591370 · NCT03405454
  23. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
    Nanda R, Liu MC, Yau C, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32053137 · NCT01042379 (I-SPY) · Breast Neoplasms
  24. Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
    Melisi D, Oh DY, Hollebecque A, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 33688022 · NCT02734160 · Pancreatic Neoplasms
  25. RAMPART: A model for a regulatory-ready academic-led phase III trial in the adjuvant renal cell carcinoma setting.
    Meade A, Oza B, Frangou E, et al. · Contemp Clin Trials · 2021 · Derived
    PubMed: PMID 34538401 · NCT03288532 (RAMPART) · Carcinoma, Renal Cell
  26. CALLA: Efficacy and safety of concurrent and adjuvant durvalumab with chemoradiotherapy versus chemoradiotherapy alone in women with locally advanced cervical cancer: a phase III, randomized, double-blind, multicenter study.
    Mayadev J, Nunes AT, Li M, et al. · Int J Gynecol Cancer · 2021 · Derived
    PubMed: PMID 32447296 · NCT03830866 (CALLA)
  27. Prevalence, Disease-free, and Overall Survival of Contemporary Patients With Renal Cell Carcinoma Eligible for Adjuvant Checkpoint Inhibitor Trials.
    Marconi L, Sun M, Beisland C, et al. · Clin Genitourin Cancer · 2021 · Derived
    PubMed: PMID 33526329 · NCT03288532 (RAMPART) · Carcinoma, Renal Cell
  28. Cabozantinib Plus Durvalumab in Patients With Advanced Urothelial Carcinoma After Platinum Chemotherapy: Safety and Preliminary Activity of the Open-Label, Single-Arm, Phase 2 ARCADIA Trial.
    Marandino L, Raggi D, Calareso G, et al. · Clin Genitourin Cancer · 2021 · Derived
    PubMed: PMID 34006499 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  29. Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial.
    Kuon J, Hommertgen A, Krisam J, et al. · Trials · 2021 · Derived
    PubMed: PMID 32321565 · NCT03345810 (DURATION) · Carcinoma, Non-Small-Cell Lung
  30. Understanding the new therapeutic options for mesothelioma.
    Kindler HL · Lancet Oncol · 2021 · Derived
    PubMed: PMID 34499875 · NCT02899195 (PrE0505) · Mesothelioma
  31. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
    Kelley RK, Sangro B, Harris W, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 34292792 · NCT02519348 · Carcinoma, Hepatocellular
  32. Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
    I-SPY2 Trial Consortium, Yee D, DeMichele AM, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32701140 · NCT01042379 (I-SPY) · Breast Neoplasms
  33. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection: The Phase 2 DURVAST Study.
    Gonzalez-Cao M, Morán T, Dalmau J, et al. · JAMA Oncol · 2021 · Derived
    PubMed: PMID 32271353 · NCT03094286 · Neoplasms
  34. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW, Dvorkin M, Chen Y, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 33285097 · NCT03043872 (CASPIAN) · Small Cell Lung Carcinoma
  35. Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer.
    Ghebeh H, Al-Sayed A, Eiada R, et al. · Sci Rep · 2021 · Derived
    PubMed: PMID 34580336 · NCT02628132 · Breast Neoplasms
  36. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
    Gao J, Navai N, Alhalabi O, et al. · Nat Med · 2021 · Derived
    PubMed: PMID 33046869 · NCT02812420 · Hydronephrosis
  37. Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    Fumet JD, Limagne E, Thibaudin M, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 32778095 · NCT04169841 (GUIDE2REPAIR)
  38. Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results.
    Ferrarotto R, Bell D, Rubin ML, et al. · Clin Cancer Res · 2021 · Derived
    PubMed: PMID 32269052 · NCT03144778 · Squamous Cell Carcinoma of Head and Neck
  39. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
    Ernst M, Oeser A, Besiroglu B, et al. · Cochrane Database Syst Rev · 2021 · Derived
    PubMed: PMID 34515338 · NCT03310619 (PLATFORM) · Lymphoma, Large B-Cell, Diffuse
  40. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer.
    Engebraaten O, Yau C, Berg K, et al. · Nat Commun · 2021 · Derived
    PubMed: PMID 34741021 · NCT01042379 (I-SPY) · Breast Neoplasms
  41. Neo-CheckRay: radiation therapy and adenosine pathway blockade to increase benefit of immuno-chemotherapy in early stage luminal B breast cancer, a randomized phase II trial.
    De Caluwé A, Buisseret L, Poortmans P, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 34362344 · NCT03875573 (Neo-CheckRay) · Breast Neoplasms
  42. MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
    Chien AJ, Tripathy D, Albain KS, et al. · J Clin Oncol · 2021 · Derived
    PubMed: PMID 32031889 · NCT01042379 (I-SPY) · Breast Neoplasms
  43. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
    Bozorgmehr F, Chung I, Christopoulos P, et al. · BMC Cancer · 2021 · Derived
    PubMed: PMID 32842974 · NCT04351256 (TRADE-hypo) · Carcinoma, Non-Small-Cell Lung
  44. Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial.
    Boilève A, Hilmi M, Gougis P, et al. · Eur J Cancer · 2021 · Derived
    PubMed: PMID 33279854 · NCT03704480 (IMMUNO-BIL)
  45. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial.
    Antill Y, Kok PS, Robledo K, et al. · J Immunother Cancer · 2021 · Derived
    PubMed: PMID 34103352 · NCT03015129 · Recurrence
  46. Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.
    Altorki NK, McGraw TE, Borczuk AC, et al. · Lancet Oncol · 2021 · Derived
    PubMed: PMID 34015311 · NCT02904954 · Carcinoma, Non-Small-Cell Lung
  47. Chemotherapeutic agent-mediated elimination of myeloid-derived suppressor cells.
    Wang Z, Till B, Gao Q, et al. · Oncoimmunology · 2021 · Background
    PubMed: PMID 28811975 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  48. XPO1 inhibition synergizes with PARP1 inhibition in small cell lung cancer by targeting nuclear transport of FOXO3a.
    Wang J, Sun T, Meng Z, et al. · Cancer Lett · 2021 · Background
    PubMed: PMID 33493586 · NCT07172412
  49. Utilization and factors precluding the initiation of consolidative durvalumab in unresectable stage III non-small cell lung cancer.
    Shaverdian N, Offin MD, Rimner A, et al. · Radiother Oncol · 2021 · Background
    PubMed: PMID 31786421 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  50. Cardiac Irradiation Predicts Activity Decline in Patients Receiving Concurrent Chemoradiation for Locally Advanced Lung Cancer.
    Paul S, Bodner WR, Garg M, et al. · Int J Radiat Oncol Biol Phys · 2021 · Background
    PubMed: PMID 32497682 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  51. Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study.
    Mielgo-Rubio X, Garde-Noguera J, Juan O, et al. · World J Clin Oncol · 2021 · Background
    PubMed: PMID 33437660 · NCT05484583 · Lung Neoplasms
  52. Association of severe lymphopenia and disease progression in unresectable locally advanced non-small cell lung cancer treated with definitive chemoradiation and immunotherapy.
    Friedes C, Chakrabarti T, Olson S, et al. · Lung Cancer · 2021 · Background
    PubMed: PMID 33611224 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  53. Interaction between lymphopenia, radiotherapy technique, dosimetry, and survival outcomes in lung cancer patients receiving combined immunotherapy and radiotherapy.
    Chen D, Patel RR, Verma V, et al. · Radiother Oncol · 2021 · Background
    PubMed: PMID 32525003 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  54. Predicting per-lesion local recurrence in locally advanced non-small cell lung cancer following definitive radiation therapy using pre- and mid-treatment metabolic tumor volume.
    Binkley MS, Koenig JL, Kashyap M, et al. · Radiat Oncol · 2021 · Background
    PubMed: PMID 32429982 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  55. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Basch E, Becker C, Rogak LJ, et al. · Clin Trials · 2021 · Background
    PubMed: PMID 33258687 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  56. Radiotherapy-Related Lymphopenia Affects Overall Survival in Patients With Lung Cancer.
    Abravan A, Faivre-Finn C, Kennedy J, et al. · J Thorac Oncol · 2021 · Background
    PubMed: PMID 32553694 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung

2020 (27 papers)

  1. Liquid biopsies in bladder cancer-did we find the Holy Grail for biomarker analyses?
    Rink M, Shariat SF, Soave A, et al. · Transl Androl Urol · 2020 · Trial result
    PubMed: PMID 28078238 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  2. The National Lung Matrix Trial of personalized therapy in lung cancer.
    Middleton G, Fletcher P, Popat S, et al. · Nature · 2020 · Trial result
    PubMed: PMID 32669708 · NCT02664935 · Carcinoma, Non-Small-Cell Lung
  3. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
    Chia S, Bedard PL, Hilton J, et al. · Oncologist · 2020 · Trial result
    PubMed: PMID 31420468 · NCT02649686 · Breast Neoplasms
  4. Cost-effectiveness and Net Monetary Benefit of Durvalumab Consolidation Therapy Versus No Consolidation Therapy After Chemoradiotherapy in Stage III Non-small Cell Lung Cancer in the Italian National Health Service.
    Armeni P, Borsoi L, Fornaro G, et al. · Clin Ther · 2020 · Trial result
    PubMed: PMID 32354495 · NCT05683977 (ARSENAL) · Small Cell Lung Carcinoma
  5. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
    Zimmer AS, Nichols E, Cimino-Mathews A, et al. · J Immunother Cancer · 2020 · Derived
    PubMed: PMID 31345267 · NCT02484404 · Breast Neoplasms
  6. Interventions for mycosis fungoides.
    Valipour A, Jäger M, Wu P, et al. · Cochrane Database Syst Rev · 2020 · Derived
    PubMed: PMID 32632956 · NCT03011814 · Lymphoma, T-Cell, Cutaneous
  7. Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO.
    Thibault C, Elaidi R, Vano YA, et al. · Bull Cancer · 2020 · Derived
    PubMed: PMID 32620213 · NCT03549715 (NEMIO)
  8. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
    Schmid S, Früh M, Peters S, et al. · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32027845 · NCT03944772 (ORCHARD) · Carcinoma, Non-Small-Cell Lung
  9. PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma.
    Ribas A, Algazi A, Ascierto PA, et al. · Nat Commun · 2020 · Derived
    PubMed: PMID 33288749 · NCT02027961 · Neoplasm Metastasis
  10. Proton beam or photon beam radiotherapy in the treatment of non-small-cell lung cancer.
    Ramella S, D'Angelillo RM · Lancet Oncol · 2020 · Derived
    PubMed: PMID 32615102 · NCT01993810 · Carcinoma, Non-Small-Cell Lung
  11. An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3045), AMBITION.
    Lee JY, Yi JY, Kim HS, et al. · Jpn J Clin Oncol · 2020 · Derived
    PubMed: PMID 31671191 · NCT03699449
  12. A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D.
    Lee JY, Kim JW, Lim MC, et al. · J Gynecol Oncol · 2020 · Derived
    PubMed: PMID 31576697 · NCT03899610 (KGOG3046) · Ovarian Neoplasms
  13. Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models.
    Wang Z, Sun K, Xiao Y, et al. · Sci Rep · 2020 · Background
    PubMed: PMID 30755715 · NCT05092412 · Lung Neoplasms
  14. Current Diagnosis and Management of Small-Cell Lung Cancer.
    Wang S, Zimmermann S, Parikh K, et al. · Mayo Clin Proc · 2020 · Background
    PubMed: PMID 31378235 · NCT05683977 (ARSENAL) · Small Cell Lung Carcinoma
  15. Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study.
    Thomas A, Vilimas R, Trindade C, et al. · J Thorac Oncol · 2020 · Background
    PubMed: PMID 31063862 · NCT05092412 · Lung Neoplasms
  16. Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer.
    Sen T, Rodriguez BL, Chen L, et al. · Cancer Discov · 2020 · Background
    PubMed: PMID 30777870 · NCT05092412 · Lung Neoplasms
  17. Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression.
    Ricciuti B, Genova C, Bassanelli M, et al. · Clin Lung Cancer · 2020 · Background
    PubMed: PMID 30910574 · NCT05568212
  18. Stereotactic ablative radiotherapy for the comprehensive treatment of 1-3 Oligometastatic tumors (SABR-COMET-3): study protocol for a randomized phase III trial.
    Olson R, Mathews L, Liu M, et al. · BMC Cancer · 2020 · Background
    PubMed: PMID 32370765 · NCT05484583 · Lung Neoplasms
  19. Daily Step Counts: A New Prognostic Factor in Locally Advanced Non-Small Cell Lung Cancer?
    Ohri N, Halmos B, Bodner WR, et al. · Int J Radiat Oncol Biol Phys · 2020 · Background
    PubMed: PMID 31398385 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  20. Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response.
    Kang J, Jeong JH, Hwang HS, et al. · Cancer Res Treat · 2020 · Background
    PubMed: PMID 32019287 · NCT04308174 (DEBATE) · Biliary Tract Neoplasms
  21. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
    Finn RS, Qin S, Ikeda M, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 32402160 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  22. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.
    Domchek SM, Postel-Vinay S, Im SA, et al. · Lancet Oncol · 2020 · Background
    PubMed: PMID 32771088 · NCT05222971 (OPTIMUM) · Biliary Tract Neoplasms
  23. Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies.
    Comunanza V, Bussolino F · Front Cell Dev Biol · 2020 · Background
    PubMed: PMID 29270405 · NCT04696848 · Colorectal Neoplasms
  24. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.
    Chalabi M, Fanchi LF, Dijkstra KK, et al. · Nat Med · 2020 · Background
    PubMed: PMID 32251400 · NCT04817826 (INFINITY) · Stomach Neoplasms
  25. Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
    Chae H, Kim D, Yoo C, et al. · Eur J Cancer · 2020 · Background
    PubMed: PMID 31476489 · NCT05222971 (OPTIMUM) · Biliary Tract Neoplasms
  26. Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung Cancer.
    Bradley JD, Hu C, Komaki RR, et al. · J Clin Oncol · 2020 · Background
    PubMed: PMID 31841363 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  27. Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience.
    Botticella A, Mezquita L, Le Pechoux C, et al. · Ther Adv Respir Dis · 2020 · Background
    PubMed: PMID 31686616 · NCT05568212

2019 (24 papers)

  1. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L, Dvorkin M, Chen Y, et al. · Lancet · 2019 · Derived
    PubMed: PMID 31590988 · NCT03043872 (CASPIAN) · Small Cell Lung Carcinoma
  2. An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis.
    Necchi A, Giannatempo P, Raggi D, et al. · Eur Urol · 2019 · Derived
    PubMed: PMID 30243800 · NCT03081923 (APACHE) · Neoplasms, Germ Cell and Embryonal
  3. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
    Karzai F, VanderWeele D, Madan RA, et al. · J Immunother Cancer · 2019 · Derived
    PubMed: PMID 30514390 · NCT02484404 · Breast Neoplasms
  4. Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach.
    Galot R, Le Tourneau C, Guigay J, et al. · Ann Oncol · 2019 · Derived
    PubMed: PMID 30307465 · NCT03088059 (UPSTREAM) · Squamous Cell Carcinoma of Head and Neck
  5. Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.
    Bahig H, Aubin F, Stagg J, et al. · BMC Cancer · 2019 · Derived
    PubMed: PMID 30642290 · NCT03283605 · Squamous Cell Carcinoma of Head and Neck
  6. Chemoradiotherapy Versus Chemotherapy Alone for Unresected Nonmetastatic Gallbladder Cancer: National Practice Patterns and Outcomes.
    Verma V, Surkar SM, Brooks ED, et al. · J Natl Compr Canc Netw · 2019 · Background
    PubMed: PMID 29295882 · NCT06214572 (RUGB) · Biliary Tract Neoplasms
  7. Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
    Teo MY, Seier K, Ostrovnaya I, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 29489427 · NCT05222971 (OPTIMUM) · Biliary Tract Neoplasms
  8. Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
    Reck M, Rodríguez-Abreu D, Robinson AG, et al. · J Clin Oncol · 2019 · Background
    PubMed: PMID 30620668 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  9. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
    Qiao M, Jiang T, Ren S, et al. · Clin Lung Cancer · 2019 · Background
    PubMed: PMID 28716463 · NCT05568212
  10. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
    Palma DA, Olson R, Harrow S, et al. · Lancet · 2019 · Background
    PubMed: PMID 30982687 · NCT05484583 · Lung Neoplasms
  11. Temozolomide plus PARP Inhibition in Small-Cell Lung Cancer: Could Patient-Derived Xenografts Accelerate Discovery of Biomarker Candidates?
    Pacheco JM, Byers LA · Cancer Discov · 2019 · Background
    PubMed: PMID 31575562 · NCT05092412 · Lung Neoplasms
  12. Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    Ohri N, Bodner WR, Kabarriti R, et al. · Int J Radiat Oncol Biol Phys · 2019 · Background
    PubMed: PMID 29249527 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  13. Percutaneous irreversible electroporation of hepatocellular carcinoma: Contrast-enhanced ultrasound-findings during 1-year follow-up.
    Niessen C, Beyer LP, Haimerl M, et al. · Clin Hemorheol Microcirc · 2019 · Background
    PubMed: PMID 30584122 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  14. Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations.
    Nault JC, Sutter O, Nahon P, et al. · J Hepatol · 2019 · Background
    PubMed: PMID 29031662 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  15. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Lyu N, Kong Y, Mu L, et al. · J Hepatol · 2019 · Background
    PubMed: PMID 29471013 · NCT04945720 · Carcinoma, Hepatocellular
  16. Is There Value in Molecular Profiling of Soft-Tissue Sarcoma?
    Italiano A · Curr Treat Options Oncol · 2019 · Background
    PubMed: PMID 30523434 · NCT03784014 (MULTISARC) · Neoplasm Metastasis
  17. Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin.
    Hyung J, Kim B, Yoo C, et al. · Cancer Res Treat · 2019 · Background
    PubMed: PMID 30282446 · NCT05222971 (OPTIMUM) · Biliary Tract Neoplasms
  18. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.
    Horn L, Mansfield AS, Szczęsna A, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 30280641 · NCT05683977 (ARSENAL) · Small Cell Lung Carcinoma
  19. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    Golan T, Hammel P, Reni M, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 31157963 · NCT05222971 (OPTIMUM) · Biliary Tract Neoplasms
  20. Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study.
    Gandara DR, von Pawel J, Mazieres J, et al. · J Thorac Oncol · 2019 · Background
    PubMed: PMID 30217492 · NCT05568212
  21. Combined stereotactic body radiotherapy and trans-arterial chemoembolization as initial treatment in BCLC stage B-C hepatocellular carcinoma.
    Chiang CL, Chan MKH, Yeung CSY, et al. · Strahlenther Onkol · 2019 · Background
    PubMed: PMID 30413833 · NCT04988945 · Carcinoma, Hepatocellular
  22. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary.
    Brahmer JR, Lacchetti C, Thompson JA, et al. · J Oncol Pract · 2019 · Background
    PubMed: PMID 29517954 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  23. Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria.
    Bonomi P, Blumenthal G, Ferris AS, et al. · J Thorac Oncol · 2019 · Background
    PubMed: PMID 29793646 · NCT04441138 (ESR1814205) · Carcinoma, Non-Small-Cell Lung
  24. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
    Antonia SJ, Villegas A, Daniel D, et al. · N Engl J Med · 2019 · Background
    PubMed: PMID 30280658 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung

2018 (19 papers)

  1. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
    Necchi A, Sonpavde G, Lo Vullo S, et al. · Eur Urol · 2018 · Trial result
    PubMed: PMID 27726966 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  2. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.
    Severson TM, Wolf DM, Yau C, et al. · Breast Cancer Res · 2018 · Derived
    PubMed: PMID 28851423 · NCT01042379 (I-SPY) · Breast Neoplasms
  3. Survival changes in patients with small cell lung cancer and disparities between different sexes, socioeconomic statuses and ages.
    Wang S, Tang J, Sun T, et al. · Sci Rep · 2018 · Background
    PubMed: PMID 28465554 · NCT05683977 (ARSENAL) · Small Cell Lung Carcinoma
  4. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.
    Socinski MA, Jotte RM, Cappuzzo F, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29863955 · NCT05568212
  5. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy.
    Shiraishi Y, Fang P, Xu C, et al. · Radiother Oncol · 2018 · Background
    PubMed: PMID 29248170 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  6. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.
    Paz-Ares L, Luft A, Vicente D, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 30280635 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  7. What's New in SCLC? A Review.
    Oronsky B, Reid TR, Oronsky A, et al. · Neoplasia · 2018 · Background
    PubMed: PMID 28888101 · NCT05683977 (ARSENAL) · Small Cell Lung Carcinoma
  8. Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors.
    Niessen C, Thumann S, Beyer L, et al. · Sci Rep · 2018 · Background
    PubMed: PMID 28266600 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  9. ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer.
    Nestle U, De Ruysscher D, Ricardi U, et al. · Radiother Oncol · 2018 · Background
    PubMed: PMID 29605476 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  10. FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
    Lyu N, Lin Y, Kong Y, et al. · Gut · 2018 · Background
    PubMed: PMID 28592441 · NCT04945720 · Carcinoma, Hepatocellular
  11. Association between intensity modulated radiotherapy and survival in patients with stage III non-small cell lung cancer treated with chemoradiotherapy.
    Koshy M, Malik R, Spiotto M, et al. · Lung Cancer · 2018 · Background
    PubMed: PMID 28625640 · NCT04441138 (ESR1814205) · Carcinoma, Non-Small-Cell Lung
  12. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S, Xia W, Yamaguchi H, et al. · Clin Cancer Res · 2018 · Background
    PubMed: PMID 28167507 · NCT05222971 (OPTIMUM) · Biliary Tract Neoplasms
  13. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29658856 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  14. Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.
    Forde PM, Chaft JE, Smith KN, et al. · N Engl J Med · 2018 · Background
    PubMed: PMID 29658848 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  15. Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025.
    Escudier B, Motzer RJ, Sharma P, et al. · Eur Urol · 2018 · Background
    PubMed: PMID 28410865 · NCT05568212
  16. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
    El-Khoueiry AB, Sangro B, Yau T, et al. · Lancet · 2018 · Background
    PubMed: PMID 28434648 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  17. Randomized Phase II Study of Preoperative Chemoradiotherapy ± Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-Small Cell Lung Cancer: NRG Oncology RTOG 0839.
    Edelman MJ, Hu C, Le QT, et al. · J Thorac Oncol · 2018 · Background
    PubMed: PMID 28629896 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  18. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer.
    De Ruysscher D, Faivre-Finn C, Moeller D, et al. · Radiother Oncol · 2018 · Background
    PubMed: PMID 28666551 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  19. Cardiac dose is associated with immunosuppression and poor survival in locally advanced non-small cell lung cancer.
    Contreras JA, Lin AJ, Weiner A, et al. · Radiother Oncol · 2018 · Background
    PubMed: PMID 29859754 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung

2017 (32 papers)

  1. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
    Zehir A, Benayed R, Shah RH, et al. · Nat Med · 2017 · Trial result
    PubMed: PMID 28481359 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  2. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
    Seymour L, Bogaerts J, Perrone A, et al. · Lancet Oncol · 2017 · Trial result
    PubMed: PMID 28271869 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  3. Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
    Powles T, O'Donnell PH, Massard C, et al. · JAMA Oncol · 2017 · Trial result
    PubMed: PMID 28817753 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  4. Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis.
    Necchi A, Pond GR, Raggi D, et al. · Clin Genitourin Cancer · 2017 · Trial result
    PubMed: PMID 27324051 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  5. Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade.
    McNamara MJ, Hilgart-Martiszus I, Barragan Echenique DM, et al. · Cancer Immunol Res · 2017 · Trial result
    PubMed: PMID 27262113 · NCT05000710 (CORAL-Lung) · Neoplasm Metastasis
  6. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer.
    Massard C, Gordon MS, Sharma S, et al. · J Clin Oncol · 2017 · Trial result
    PubMed: PMID 27269937 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  7. Bladder cancer.
    Kamat AM, Hahn NM, Efstathiou JA, et al. · Lancet · 2017 · Trial result
    PubMed: PMID 27345655 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  8. Beyond melanoma: inhibiting the PD-1/PD-L1 pathway in solid tumors.
    Gentzler R, Hall R, Kunk PR, et al. · Immunotherapy · 2017 · Trial result
    PubMed: PMID 27140411 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  9. The synergistic effect of radiotherapy and immunotherapy: A promising but not simple partnership.
    Chajon E, Castelli J, Marsiglia H, et al. · Crit Rev Oncol Hematol · 2017 · Trial result
    PubMed: PMID 28259287 · NCT05000710 (CORAL-Lung) · Neoplasm Metastasis
  10. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
    Antonia SJ, Villegas A, Daniel D, et al. · N Engl J Med · 2017 · Trial result
    PubMed: PMID 28885881 · NCT05000710 (CORAL-Lung) · Neoplasm Metastasis
  11. Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy.
    Wang K, Eblan MJ, Deal AM, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28113017 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  12. The IASLC Lung Cancer Staging Project: Proposals for Coding T Categories for Subsolid Nodules and Assessment of Tumor Size in Part-Solid Tumors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer.
    Travis WD, Asamura H, Bankier AA, et al. · J Thorac Oncol · 2017 · Background
    PubMed: PMID 27107787 · NCT05683977 (ARSENAL) · Small Cell Lung Carcinoma
  13. Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series.
    Sutter O, Calvo J, N'Kontchou G, et al. · Radiology · 2017 · Background
    PubMed: PMID 28453431 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  14. Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.
    Stinchcombe TE, Zhang Y, Vokes EE, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28493811 · NCT04441138 (ESR1814205) · Carcinoma, Non-Small-Cell Lung
  15. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
    Steuer CE, Behera M, Ernani V, et al. · JAMA Oncol · 2017 · Background
    PubMed: PMID 27978552 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  16. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
    Rizvi NA, Hellmann MD, Brahmer JR, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 27354481 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  17. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    Reck M, Luft A, Szczesna A, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 27458307 · NCT05092412 · Lung Neoplasms
  18. Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer.
    Qin A, Coffey DG, Warren EH, et al. · Cancer Med · 2017 · Background
    PubMed: PMID 27416962 · NCT04441138 (ESR1814205) · Carcinoma, Non-Small-Cell Lung
  19. A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study.
    Planchard D, Yokoi T, McCleod MJ, et al. · Clin Lung Cancer · 2017 · Background
    PubMed: PMID 27265743 · NCT05092412 · Lung Neoplasms
  20. Continuous Activity Monitoring During Concurrent Chemoradiotherapy.
    Ohri N, Kabarriti R, Bodner WR, et al. · Int J Radiat Oncol Biol Phys · 2017 · Background
    PubMed: PMID 28332990 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  21. 18F-Fluorodeoxyglucose/Positron Emission Tomography Predicts Patterns of Failure After Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    Ohri N, Bodner WR, Halmos B, et al. · Int J Radiat Oncol Biol Phys · 2017 · Background
    PubMed: PMID 28068244 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  22. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.
    Nicholson AG, Chansky K, Crowley J, et al. · J Thorac Oncol · 2017 · Background
    PubMed: PMID 26723244 · NCT05683977 (ARSENAL) · Small Cell Lung Carcinoma
  23. Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials.
    Long GV, Weber JS, Larkin J, et al. · JAMA Oncol · 2017 · Background
    PubMed: PMID 28662232 · NCT05568212
  24. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
    Langer CJ, Gadgeel SM, Borghaei H, et al. · Lancet Oncol · 2017 · Background
    PubMed: PMID 27745820 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  25. Immunogenic cell death in cancer and infectious disease.
    Galluzzi L, Buqué A, Kepp O, et al. · Nat Rev Immunol · 2017 · Background
    PubMed: PMID 27748397 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  26. A Randomized Phase 2 Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy-Induced Esophagitis During the Treatment of Lung Cancer: Results of NRG Oncology RTOG 1012.
    Fogh SE, Deshmukh S, Berk LB, et al. · Int J Radiat Oncol Biol Phys · 2017 · Background
    PubMed: PMID 28244415 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  27. Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.
    Dess RT, Sun Y, Matuszak MM, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28301264 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  28. Radiotherapy in combination with immune checkpoint inhibitors.
    De Ruysscher D, Reynders K, Van Limbergen E, et al. · Curr Opin Oncol · 2017 · Background
    PubMed: PMID 28085679 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  29. Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial.
    Chun SG, Hu C, Choy H, et al. · J Clin Oncol · 2017 · Background
    PubMed: PMID 28034064 · NCT04441138 (ESR1814205) · Carcinoma, Non-Small-Cell Lung
  30. Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small-Animal Model.
    Bulvik BE, Rozenblum N, Gourevich S, et al. · Radiology · 2017 · Background
    PubMed: PMID 27429143 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  31. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC).
    Bhutiani N, Philips P, Scoggins CR, et al. · HPB (Oxford) · 2017 · Background
    PubMed: PMID 27346140 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  32. Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?
    Bernstein MB, Krishnan S, Hodge JW, et al. · Nat Rev Clin Oncol · 2017 · Background
    PubMed: PMID 26951040 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung

2016 (30 papers)

  1. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis.
    Raggi D, Miceli R, Sonpavde G, et al. · Ann Oncol · 2016 · Trial result
    PubMed: PMID 26487582 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  2. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer.
    Rugo HS, Olopade OI, DeMichele A, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 27406347 · NCT01042379 (I-SPY) · Breast Neoplasms
  3. Adaptive Randomization of Neratinib in Early Breast Cancer.
    Park JW, Liu MC, Yee D, et al. · N Engl J Med · 2016 · Derived
    PubMed: PMID 27406346 · NCT01042379 (I-SPY) · Breast Neoplasms
  4. The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer.
    Middleton G, Crack LR, Popat S, et al. · Ann Oncol · 2016 · Derived
    PubMed: PMID 26410619 · NCT02154490
  5. Targeting CD73 in the tumor microenvironment with MEDI9447.
    Hay CM, Sult E, Huang Q, et al. · Oncoimmunology · 2016 · Derived
    PubMed: PMID 27622077 · NCT02503774 · Carcinoma, Non-Small-Cell Lung
  6. Annual report of the Committee on Gynecologic Oncology, the Japan Society of Obstetrics and Gynecology.
    Yamagami W, Aoki D · J Obstet Gynaecol Res · 2016 · Background
    PubMed: PMID 25370711 · NCT03405454
  7. The positive prognostic effect of stromal CD8+ tumor-infiltrating T cells is restrained by the expression of HLA-E in non-small cell lung carcinoma.
    Talebian Yazdi M, van Riet S, van Schadewijk A, et al. · Oncotarget · 2016 · Background
    PubMed: PMID 26658106 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  8. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
    Stewart R, Morrow M, Hammond SA, et al. · Cancer Immunol Res · 2016 · Background
    PubMed: PMID 25943534 · NCT04441138 (ESR1814205) · Carcinoma, Non-Small-Cell Lung
  9. Cancer statistics, 2016.
    Siegel RL, Miller KD, Jemal A, et al. · CA Cancer J Clin · 2016 · Background
    PubMed: PMID 26742998 · NCT03085849 · Small Cell Lung Carcinoma
  10. Ablative therapies: Advantages and disadvantages of radiofrequency, cryotherapy, microwave and electroporation methods, or how to choose the right method for an individual patient?
    Seror O · Diagn Interv Imaging · 2016 · Background
    PubMed: PMID 25981214 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  11. PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Senan S, Brade A, Wang LH, et al. · J Clin Oncol · 2016 · Background
    PubMed: PMID 26811519 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  12. Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer.
    Ripley RT, Suzuki K, Tan KS, et al. · J Thorac Cardiovasc Surg · 2016 · Background
    PubMed: PMID 26614420 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  13. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
    Reck M, Rodríguez-Abreu D, Robinson AG, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 27718847 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  14. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
    Rajani KR, Vile RG · Viruses · 2016 · Background
    PubMed: PMID 26580645 · NCT03206073 · Colorectal Neoplasms
  15. Percutaneous Ablation of Hepatic Tumors Using Irreversible Electroporation: A Prospective Safety and Midterm Efficacy Study in 34 Patients.
    Niessen C, Beyer LP, Pregler B, et al. · J Vasc Interv Radiol · 2016 · Background
    PubMed: PMID 26922979 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  16. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J, Lee-Gabel L, Nadeau MC, et al. · J Oncol Pharm Pract · 2016 · Background
    PubMed: PMID 24917416 · NCT02628132 · Breast Neoplasms
  17. Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy.
    Kohlhapp FJ, Kaufman HL · Clin Cancer Res · 2016 · Background
    PubMed: PMID 26719429 · NCT03206073 · Colorectal Neoplasms
  18. Current clinical trials testing the combination of immunotherapy with radiotherapy.
    Kang J, Demaria S, Formenti S, et al. · J Immunother Cancer · 2016 · Background
    PubMed: PMID 27660705 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  19. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
    Herbst RS, Baas P, Kim DW, et al. · Lancet · 2016 · Background
    PubMed: PMID 26712084 · NCT03130764 · Carcinoma, Non-Small-Cell Lung
  20. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer.
    Goldstraw P, Chansky K, Crowley J, et al. · J Thorac Oncol · 2016 · Background
    PubMed: PMID 26762738 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  21. Replication and validation of higher order models demonstrated that a summary score for the EORTC QLQ-C30 is robust.
    Giesinger JM, Kieffer JM, Fayers PM, et al. · J Clin Epidemiol · 2016 · Background
    PubMed: PMID 26327487 · NCT02336165 · Glioblastoma
  22. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the M Descriptors in the Forthcoming Eighth Edition of the TNM Classification of Lung Cancer.
    Eberhardt WE, Mitchell A, Crowley J, et al. · J Thorac Oncol · 2016 · Background
    PubMed: PMID 26536193 · NCT05683977 (ARSENAL) · Small Cell Lung Carcinoma
  23. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.
    Darling GE, Li F, Patsios D, et al. · Eur J Cardiothorac Surg · 2016 · Background
    PubMed: PMID 25567960 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  24. Irreversible Electroporation Can Effectively Ablate Hepatocellular Carcinoma to Complete Pathologic Necrosis.
    Cheng RG, Bhattacharya R, Yeh MM, et al. · J Vasc Interv Radiol · 2016 · Background
    PubMed: PMID 26119204 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  25. Postoperative radiotherapy for non-small cell lung cancer.
    Burdett S, Rydzewska L, Tierney J, et al. · Cochrane Database Syst Rev · 2016 · Background
    PubMed: PMID 27727451 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  26. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J, Takayama T, Mazzaferro V, et al. · Lancet Oncol · 2016 · Background
    PubMed: PMID 26361969 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  27. Additive antitumour response to the rabbit VX2 hepatoma by combined radio frequency ablation and toll like receptor 9 stimulation.
    Behm B, Di Fazio P, Michl P, et al. · Gut · 2016 · Background
    PubMed: PMID 25524262 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  28. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
    Apetoh L, Ladoire S, Coukos G, et al. · Ann Oncol · 2016 · Background
    PubMed: PMID 25922066 · NCT05568212
  29. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.
    Antonia S, Goldberg SB, Balmanoukian A, et al. · Lancet Oncol · 2016 · Background
    PubMed: PMID 26858122 · NCT03130764 · Carcinoma, Non-Small-Cell Lung
  30. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: significance in claudin-low breast cancer cells.
    Alsuliman A, Colak D, Al-Harazi O, et al. · Mol Cancer · 2016 · Background
    PubMed: PMID 26245467 · NCT02628132 · Breast Neoplasms

2015 (20 papers)

  1. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.
    Vétizou M, Pitt JM, Daillère R, et al. · Science · 2015 · Trial result
    PubMed: PMID 26541610 · NCT05000710 (CORAL-Lung) · Neoplasm Metastasis
  2. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.
    Reardon ZD, Patel SG, Zaid HB, et al. · Eur Urol · 2015 · Trial result
    PubMed: PMID 24472710 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  3. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer.
    Powles T, Eder JP, Fine GD, et al. · Nature · 2015 · Trial result
    PubMed: PMID 25428503 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  4. Population pharmacokinetic and pharmacodynamic analysis of tremelimumab in patients with metastatic melanoma.
    Wang E, Kang D, Bae KS, et al. · J Clin Pharmacol · 2015 · Background
    PubMed: PMID 24737343 · NCT05568212
  5. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
    Twyman-Saint Victor C, Rech AJ, Maity A, et al. · Nature · 2015 · Background
    PubMed: PMID 25754329 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  6. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
    Trinchet JC, Bourcier V, Chaffaut C, et al. · Hepatology · 2015 · Background
    PubMed: PMID 25678021 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  7. Global cancer statistics, 2012.
    Torre LA, Bray F, Siegel RL, et al. · CA Cancer J Clin · 2015 · Background
    PubMed: PMID 25651787 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  8. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial.
    Slotman BJ, van Tinteren H, Praag JO, et al. · Lancet · 2015 · Background
    PubMed: PMID 25230595 · NCT05092412 · Lung Neoplasms
  9. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
    Schadendorf D, Hodi FS, Robert C, et al. · J Clin Oncol · 2015 · Background
    PubMed: PMID 25667295 · NCT04988945 · Carcinoma, Hepatocellular
  10. Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial.
    Pless M, Stupp R, Ris HB, et al. · Lancet · 2015 · Background
    PubMed: PMID 26275735 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  11. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N, Piperdi B, Garg MK, et al. · Lung Cancer · 2015 · Background
    PubMed: PMID 25468149 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  12. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma.
    Lee JH, Lee JH, Lim YS, et al. · Gastroenterology · 2015 · Background
    PubMed: PMID 25747273 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  13. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.
    Golden EB, Chhabra A, Chachoua A, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 26095785 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  14. Patterns of locoregional failure in stage III non-small cell lung cancer treated with definitive chemoradiation therapy.
    Garg S, Gielda BT, Kiel K, et al. · Pract Radiat Oncol · 2015 · Background
    PubMed: PMID 25194104 · NCT04441138 (ESR1814205) · Carcinoma, Non-Small-Cell Lung
  15. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.
    Ferlay J, Soerjomataram I, Dikshit R, et al. · Int J Cancer · 2015 · Background
    PubMed: PMID 25220842 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  16. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.
    Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25840693 · NCT03130764 · Carcinoma, Non-Small-Cell Lung
  17. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer.
    De Leyn P, Dooms C, Kuzdzal J, et al. · Eur J Cardiothorac Surg · 2015 · Background
    PubMed: PMID 24578407 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  18. Small cell lung carcinoma: staging, imaging, and treatment considerations.
    Carter BW, Glisson BS, Truong MT, et al. · Radiographics · 2015 · Background
    PubMed: PMID 25310425 · NCT05683977 (ARSENAL) · Small Cell Lung Carcinoma
  19. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD, Paulus R, Komaki R, et al. · Lancet Oncol · 2015 · Background
    PubMed: PMID 25601342 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  20. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    Borghaei H, Paz-Ares L, Horn L, et al. · N Engl J Med · 2015 · Background
    PubMed: PMID 26412456 · NCT03130764 · Carcinoma, Non-Small-Cell Lung

2014 (13 papers)

  1. Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy.
    Klug F, Prakash H, Huber PE, et al. · Cancer Cell · 2014 · Trial result
    PubMed: PMID 24209604 · NCT05000710 (CORAL-Lung) · Neoplasm Metastasis
  2. Comprehensive molecular characterization of urothelial bladder carcinoma.
    Cancer Genome Atlas Research Network · Nature · 2014 · Trial result
    PubMed: PMID 24476821 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  3. Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small-cell lung cancer? A pooled analysis of the literature.
    Tsujino K, Kurata T, Yamamoto S, et al. · J Thorac Oncol · 2014 · Background
    PubMed: PMID 23883782 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  4. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.
    Topalian SL, Sznol M, McDermott DF, et al. · J Clin Oncol · 2014 · Background
    PubMed: PMID 24590637 · NCT05568212
  5. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes.
    Tang C, Liao Z, Gomez D, et al. · Int J Radiat Oncol Biol Phys · 2014 · Background
    PubMed: PMID 25035212 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  6. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
    Sangro B, Gomez-Martin C, de la Mata M, et al. · J Hepatol · 2014 · Background
    PubMed: PMID 23466307 · NCT02821754 · Carcinoma, Hepatocellular
  7. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
    Narwal R, Roskos LK, Robbie GJ, et al. · Clin Pharmacokinet · 2014 · Background
    PubMed: PMID 23754736 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  8. Role of STAT3 in cancer metastasis and translational advances.
    Kamran MZ, Patil P, Gude RP, et al. · Biomed Res Int · 2014 · Background
    PubMed: PMID 24199193 · NCT04696848 · Colorectal Neoplasms
  9. Immunological off-target effects of standard treatments in gastrointestinal cancers.
    Duffy AG, Greten TF · Ann Oncol · 2014 · Background
    PubMed: PMID 24201974 · NCT02821754 · Carcinoma, Hepatocellular
  10. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer.
    Bracci L, Schiavoni G, Sistigu A, et al. · Cell Death Differ · 2014 · Background
    PubMed: PMID 23787994 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  11. How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?
    Bayman N, Blackhall F, McCloskey P, et al. · Lung Cancer · 2014 · Background
    PubMed: PMID 24373738 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  12. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE).
    Basch E, Reeve BB, Mitchell SA, et al. · J Natl Cancer Inst · 2014 · Background
    PubMed: PMID 25265940 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  13. Immunity, inflammation and cancer: a leading role for adenosine.
    Antonioli L, Blandizzi C, Pacher P, et al. · Nat Rev Cancer · 2014 · Background
    PubMed: PMID 24226193 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung

2013 (7 papers)

  1. Mutational heterogeneity in cancer and the search for new cancer-associated genes.
    Lawrence MS, Stojanov P, Polak P, et al. · Nature · 2013 · Trial result
    PubMed: PMID 23770567 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  2. Nivolumab plus ipilimumab in advanced melanoma.
    Wolchok JD, Kluger H, Callahan MK, et al. · N Engl J Med · 2013 · Background
    PubMed: PMID 23724867 · NCT04988945 · Carcinoma, Hepatocellular
  3. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
    Sandhu SK, Schelman WR, Wilding G, et al. · Lancet Oncol · 2013 · Background
    PubMed: PMID 23810788 · NCT05092412 · Lung Neoplasms
  4. An overview of tubulin inhibitors that interact with the colchicine binding site.
    Lu Y, Chen J, Xiao M, et al. · Pharm Res · 2013 · Background
    PubMed: PMID 22814904 · NCT04696848 · Colorectal Neoplasms
  5. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
    Ibrahim YH, García-García C, Serra V, et al. · Cancer Discov · 2013 · Background
    PubMed: PMID 22915752 · NCT03772561 (MEDIPAC)
  6. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
    Heo J, Reid T, Ruo L, et al. · Nat Med · 2013 · Background
    PubMed: PMID 23396206 · NCT03206073 · Colorectal Neoplasms
  7. Signatures of mutational processes in human cancer.
    Alexandrov LB, Nik-Zainal S, Wedge DC, et al. · Nature · 2013 · Background
    PubMed: PMID 23945592 · NCT05568212

2012 (17 papers)

  1. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial).
    Lin C, Buxton MB, Moore D, et al. · Breast Cancer Res Treat · 2012 · Trial result
    PubMed: PMID 21796368 · NCT01042379 (I-SPY) · Breast Neoplasms
  2. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL.
    Hylton NM, Blume JD, Bernreuter WK, et al. · Radiology · 2012 · Trial result
    PubMed: PMID 22623692 · NCT01042379 (I-SPY) · Breast Neoplasms
  3. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657.
    Esserman LJ, Berry DA, DeMichele A, et al. · J Clin Oncol · 2012 · Trial result
    PubMed: PMID 22649152 · NCT01042379 (I-SPY) · Breast Neoplasms
  4. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Esserman LJ, Berry DA, Cheang MC, et al. · Breast Cancer Res Treat · 2012 · Trial result
    PubMed: PMID 22198468 · NCT01042379 (I-SPY) · Breast Neoplasms
  5. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans.
    Caskey M, Lefebvre F, Filali-Mouhim A, et al. · J Exp Med · 2012 · Trial result
    PubMed: PMID 22065672 · NCT03721679
  6. Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults.
    Zhang S, Shi R, Li C, et al. · J Clin Pharmacol · 2012 · Background
    PubMed: PMID 21233304 · NCT05568212
  7. Clinical trial of post-chemotherapy consolidation thoracic radiotherapy for extensive-stage small cell lung cancer.
    Yee D, Butts C, Reiman A, et al. · Radiother Oncol · 2012 · Background
    PubMed: PMID 21930323 · NCT05484583 · Lung Neoplasms
  8. What is the best way to contour lung tumors on PET scans? Multiobserver validation of a gradient-based method using a NSCLC digital PET phantom.
    Werner-Wasik M, Nelson AD, Choi W, et al. · Int J Radiat Oncol Biol Phys · 2012 · Background
    PubMed: PMID 21531085 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  9. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    Topalian SL, Hodi FS, Brahmer JR, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 22658127 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  10. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung.
    Suntharalingam M, Paulus R, Edelman MJ, et al. · Int J Radiat Oncol Biol Phys · 2012 · Background
    PubMed: PMID 22543206 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  11. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data.
    Rossi A, Di Maio M, Chiodini P, et al. · J Clin Oncol · 2012 · Background
    PubMed: PMID 22473169 · NCT05092412 · Lung Neoplasms
  12. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.
    Peifer M, Fernández-Cuesta L, Sos ML, et al. · Nat Genet · 2012 · Background
    PubMed: PMID 22941188 · NCT05092412 · Lung Neoplasms
  13. The blockade of immune checkpoints in cancer immunotherapy.
    Pardoll DM · Nat Rev Cancer · 2012 · Background
    PubMed: PMID 22437870 · NCT04988945 · Carcinoma, Hepatocellular
  14. Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: an analysis of the Radiation Therapy Oncology Group.
    Machtay M, Bae K, Movsas B, et al. · Int J Radiat Oncol Biol Phys · 2012 · Background
    PubMed: PMID 20980108 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  15. Consideration of dose limits for organs at risk of thoracic radiotherapy: atlas for lung, proximal bronchial tree, esophagus, spinal cord, ribs, and brachial plexus.
    Kong FM, Ritter T, Quint DJ, et al. · Int J Radiat Oncol Biol Phys · 2012 · Background
    PubMed: PMID 20934273 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  16. Updated survival and outcomes for older adults with inoperable stage III non-small-cell lung cancer treated with cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel: analysis of a phase III trial from the Hoosier Oncology Group (HOG) and US Oncology.
    Jalal SI, Riggs HD, Melnyk A, et al. · Ann Oncol · 2012 · Background
    PubMed: PMID 22156624 · NCT04441138 (ESR1814205) · Carcinoma, Non-Small-Cell Lung
  17. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.
    Brahmer JR, Tykodi SS, Chow LQ, et al. · N Engl J Med · 2012 · Background
    PubMed: PMID 22658128 · NCT05092412 · Lung Neoplasms

2011 (11 papers)

  1. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.
    Galsky MD, Hahn NM, Rosenberg J, et al. · J Clin Oncol · 2011 · Trial result
    PubMed: PMID 21555688 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  2. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.
    Yuan J, Adamow M, Ginsberg BA, et al. · Proc Natl Acad Sci U S A · 2011 · Background
    PubMed: PMID 21933959 · NCT05568212
  3. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
    Yap TA, Sandhu SK, Carden CP, et al. · CA Cancer J Clin · 2011 · Background
    PubMed: PMID 21205831 · NCT03772561 (MEDIPAC)
  4. Oligometastases revisited.
    Weichselbaum RR, Hellman S · Nat Rev Clin Oncol · 2011 · Background
    PubMed: PMID 21423255 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung
  5. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma.
    Platonova S, Cherfils-Vicini J, Damotte D, et al. · Cancer Res · 2011 · Background
    PubMed: PMID 21708957 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  6. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
    Paterson AM, Brown KE, Keir ME, et al. · J Immunol · 2011 · Background
    PubMed: PMID 21697456 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  7. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.
    Lesterhuis WJ, Punt CJ, Hato SV, et al. · J Clin Invest · 2011 · Background
    PubMed: PMID 21765211 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  8. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients.
    Gielda BT, Marsh JC, Zusag TW, et al. · J Thorac Oncol · 2011 · Background
    PubMed: PMID 21532501 · NCT04441138 (ESR1814205) · Carcinoma, Non-Small-Cell Lung
  9. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
    Ferlay J, Shin HR, Bray F, et al. · Int J Cancer · 2011 · Background
    PubMed: PMID 21351269 · NCT03130764 · Carcinoma, Non-Small-Cell Lung
  10. Tumor vasculature as target for therapeutic intervention.
    Fens MH, Storm G, Schiffelers RM, et al. · Expert Opin Investig Drugs · 2011 · Background
    PubMed: PMID 20946091 · NCT04696848 · Colorectal Neoplasms
  11. Accelerating identification and regulatory approval of investigational cancer drugs.
    Esserman LJ, Woodcock J · JAMA · 2011 · Background
    PubMed: PMID 22187281 · NCT01042379 (I-SPY) · Breast Neoplasms

2010 (14 papers)

  1. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
    Brody JD, Ai WZ, Czerwinski DK, et al. · J Clin Oncol · 2010 · Trial result
    PubMed: PMID 20697067 · NCT03721679
  2. Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response.
    Zerbini A, Pilli M, Laccabue D, et al. · Gastroenterology · 2010 · Background
    PubMed: PMID 20060829 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  3. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
    Wolchok JD, Hoos A, O'Day S, et al. · Clin Cancer Res · 2010 · Background
    PubMed: PMID 19934295 · NCT01975831 · Breast Neoplasms
  4. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.
    Valle J, Wasan H, Palmer DH, et al. · N Engl J Med · 2010 · Background
    PubMed: PMID 20375404 · NCT05222971 (OPTIMUM) · Biliary Tract Neoplasms
  5. Treatment options for small cell lung cancer - do we have more choice?
    Puglisi M, Dolly S, Faria A, et al. · Br J Cancer · 2010 · Background
    PubMed: PMID 20104223 · NCT05092412 · Lung Neoplasms
  6. Revised RECIST guideline version 1.1: What oncologists want to know and what radiologists need to know.
    Nishino M, Jagannathan JP, Ramaiya NH, et al. · AJR Am J Roentgenol · 2010 · Background
    PubMed: PMID 20651182 · NCT05092412 · Lung Neoplasms
  7. Use of normal tissue complication probability models in the clinic.
    Marks LB, Yorke ED, Jackson A, et al. · Int J Radiat Oncol Biol Phys · 2010 · Background
    PubMed: PMID 20171502 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  8. Radiation dose-volume effects in the lung.
    Marks LB, Bentzen SM, Deasy JO, et al. · Int J Radiat Oncol Biol Phys · 2010 · Background
    PubMed: PMID 20171521 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  9. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
    Mackay HJ, Brady MF, Oza AM, et al. · Int J Gynecol Cancer · 2010 · Background
    PubMed: PMID 20683400 · NCT03405454
  10. Differences in tumor type in low-stage versus high-stage ovarian carcinomas.
    Köbel M, Kalloger SE, Huntsman DG, et al. · Int J Gynecol Pathol · 2010 · Background
    PubMed: PMID 20407318 · NCT03405454
  11. Antitumor effect after radiofrequency ablation of murine hepatoma is augmented by an active variant of CC Chemokine ligand 3/macrophage inflammatory protein-1alpha.
    Iida N, Nakamoto Y, Baba T, et al. · Cancer Res · 2010 · Background
    PubMed: PMID 20663902 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  12. Radiation dose-volume effects in the heart.
    Gagliardi G, Constine LS, Moiseenko V, et al. · Int J Radiat Oncol Biol Phys · 2010 · Background
    PubMed: PMID 20171522 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  13. Physical activity of older Australians measured by pedometry.
    Ewald B, Duke J, Thakkinstian A, et al. · Australas J Ageing · 2010 · Background
    PubMed: PMID 19845652 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  14. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.
    Aupérin A, Le Péchoux C, Rolland E, et al. · J Clin Oncol · 2010 · Background
    PubMed: PMID 20351327 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung

2009 (9 papers)

  1. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
    Eisenhauer EA, Therasse P, Bogaerts J, et al. · Eur J Cancer · 2009 · Trial result
    PubMed: PMID 19097774 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  2. Anti-tumor immunotherapy by blockade of the PD-1/PD-L1 pathway with recombinant human PD-1-IgV.
    Zhang C, Wu S, Xue X, et al. · Cytotherapy · 2009 · Background
    PubMed: PMID 18841514 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  3. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
    Wang DD, Zhang S, Zhao H, et al. · J Clin Pharmacol · 2009 · Background
    PubMed: PMID 19620385 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  4. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors.
    Wahl RL, Jacene H, Kasamon Y, et al. · J Nucl Med · 2009 · Background
    PubMed: PMID 19403881 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  5. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.
    Okudaira K, Hokari R, Tsuzuki Y, et al. · Int J Oncol · 2009 · Background
    PubMed: PMID 19724910 · NCT05092412 · Lung Neoplasms
  6. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis.
    N'Kontchou G, Mahamoudi A, Aout M, et al. · Hepatology · 2009 · Background
    PubMed: PMID 19731239 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  7. Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer.
    Higgins K, Chino JP, Marks LB, et al. · Int J Radiat Oncol Biol Phys · 2009 · Background
    PubMed: PMID 19467798 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  8. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy.
    Barker AD, Sigman CC, Kelloff GJ, et al. · Clin Pharmacol Ther · 2009 · Background
    PubMed: PMID 19440188 · NCT01042379 (I-SPY) · Breast Neoplasms
  9. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.
    Albain KS, Swann RS, Rusch VW, et al. · Lancet · 2009 · Background
    PubMed: PMID 19632716 · NCT04062708 · Carcinoma, Non-Small-Cell Lung

2008 (10 papers)

  1. History of bacillus Calmette-Guerin and bladder cancer: an immunotherapy success story.
    Herr HW, Morales A · J Urol · 2008 · Trial result
    PubMed: PMID 17997439 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  2. Inhibitory B7-family molecules in the tumour microenvironment.
    Zou W, Chen L · Nat Rev Immunol · 2008 · Background
    PubMed: PMID 18500231 · NCT05092412 · Lung Neoplasms
  3. Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer.
    Thomas M, Rübe C, Hoffknecht P, et al. · Lancet Oncol · 2008 · Background
    PubMed: PMID 18583190 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  4. Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.
    Tarhini AA, Kirkwood JM · Expert Opin Biol Ther · 2008 · Background
    PubMed: PMID 18774925 · NCT04988945 · Carcinoma, Hepatocellular
  5. Large (>or=5.0-cm) HCCs: multipolar RF ablation with three internally cooled bipolar electrodes--initial experience in 26 patients.
    Seror O, N'Kontchou G, Ibraheem M, et al. · Radiology · 2008 · Background
    PubMed: PMID 18483229 · NCT06045975 (DUMELEP) · Carcinoma, Hepatocellular
  6. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
    Scher HI, Halabi S, Tannock I, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18309951 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  7. PD-1 and its ligands in tolerance and immunity.
    Keir ME, Butte MJ, Freeman GJ, et al. · Annu Rev Immunol · 2008 · Background
    PubMed: PMID 18173375 · NCT05092412 · Lung Neoplasms
  8. The prognostic significance of patient-reported outcomes in cancer clinical trials.
    Gotay CC, Kawamoto CT, Bottomley A, et al. · J Clin Oncol · 2008 · Background
    PubMed: PMID 18227528 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  9. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
    Fife BT, Bluestone JA · Immunol Rev · 2008 · Background
    PubMed: PMID 18759926 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  10. Analysis of duration of response in oncology trials.
    Ellis S, Carroll KJ, Pemberton K, et al. · Contemp Clin Trials · 2008 · Background
    PubMed: PMID 18187370 · NCT04696848 · Colorectal Neoplasms

2007 (6 papers)

  1. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.
    van Meerbeeck JP, Kramer GW, Van Schil PE, et al. · J Natl Cancer Inst · 2007 · Background
    PubMed: PMID 17374834 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  2. Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation.
    Reyes-Gibby CC, Chan W, Abbruzzese JL, et al. · J Pain Symptom Manage · 2007 · Background
    PubMed: PMID 17513082 · NCT02311361 · Pancreatic Neoplasms
  3. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis.
    Ng CM, Lum BL, Gimenez V, et al. · Pharm Res · 2007 · Background
    PubMed: PMID 16715358 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  4. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
    Moore MJ, Goldstein D, Hamm J, et al. · J Clin Oncol · 2007 · Background
    PubMed: PMID 17452677 · NCT02311361 · Pancreatic Neoplasms
  5. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.
    Goldstraw P, Crowley J, Chansky K, et al. · J Thorac Oncol · 2007 · Background
    PubMed: PMID 17762336 · NCT03130764 · Carcinoma, Non-Small-Cell Lung
  6. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
    Butte MJ, Keir ME, Phamduy TB, et al. · Immunity · 2007 · Background
    PubMed: PMID 17629517 · NCT05092412 · Lung Neoplasms

2006 (6 papers)

  1. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.
    Dash A, Galsky MD, Vickers AJ, et al. · Cancer · 2006 · Trial result
    PubMed: PMID 16773629 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  2. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
    Smith TJ, Khatcheressian J, Lyman GH, et al. · J Clin Oncol · 2006 · Background
    PubMed: PMID 16682719 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  3. Vascular disrupting agents.
    Pilat MJ, Lorusso PM · J Cell Biochem · 2006 · Background
    PubMed: PMID 16927308 · NCT04696848 · Colorectal Neoplasms
  4. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935.
    Jaklitsch MT, Herndon JE, DeCamp MM, et al. · J Surg Oncol · 2006 · Background
    PubMed: PMID 17039491 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  5. Radiation therapy for hepatocellular carcinoma: from palliation to cure.
    Hawkins MA, Dawson LA · Cancer · 2006 · Background
    PubMed: PMID 16541431 · NCT04988945 · Carcinoma, Hepatocellular
  6. The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.
    Ghebeh H, Mohammed S, Al-Omair A, et al. · Neoplasia · 2006 · Background
    PubMed: PMID 16611412 · NCT02628132 · Breast Neoplasms

2005 (3 papers)

  1. Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications.
    Nguewa PA, Fuertes MA, Valladares B, et al. · Prog Biophys Mol Biol · 2005 · Background
    PubMed: PMID 15561303 · NCT05092412 · Lung Neoplasms
  2. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity.
    Hirano F, Kaneko K, Tamura H, et al. · Cancer Res · 2005 · Background
    PubMed: PMID 15705911 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  3. CT-based definition of thoracic lymph node stations: an atlas from the University of Michigan.
    Chapet O, Kong FM, Quint LE, et al. · Int J Radiat Oncol Biol Phys · 2005 · Background
    PubMed: PMID 16111586 · NCT04062708 · Carcinoma, Non-Small-Cell Lung

2004 (4 papers)

  1. Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation.
    Bosio CM, Aman MJ, Grogan C, et al. · J Infect Dis · 2004 · Trial result
    PubMed: PMID 14639532 · NCT03721679
  2. Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).
    Rustin GJ, Quinn M, Thigpen T, et al. · J Natl Cancer Inst · 2004 · Background
    PubMed: PMID 15026475 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  3. BRCA1 and BRCA2: 1994 and beyond.
    Narod SA, Foulkes WD · Nat Rev Cancer · 2004 · Background
    PubMed: PMID 15343273 · NCT05092412 · Lung Neoplasms
  4. The three Es of cancer immunoediting.
    Dunn GP, Old LJ, Schreiber RD, et al. · Annu Rev Immunol · 2004 · Background
    PubMed: PMID 15032581 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung

2003 (3 papers)

  1. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
    Virág L, Szabó C · Pharmacol Rev · 2003 · Background
    PubMed: PMID 12223530 · NCT05092412 · Lung Neoplasms
  2. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis.
    Hori K, Saito S · Br J Cancer · 2003 · Background
    PubMed: PMID 14520469 · NCT04696848 · Colorectal Neoplasms
  3. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial.
    Betticher DC, Hsu Schmitz SF, Tötsch M, et al. · J Clin Oncol · 2003 · Background
    PubMed: PMID 12721251 · NCT04062708 · Carcinoma, Non-Small-Cell Lung

2002 (3 papers)

  1. Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America.
    Jänne PA, Freidlin B, Saxman S, et al. · Cancer · 2002 · Background
    PubMed: PMID 12237922 · NCT03085849 · Small Cell Lung Carcinoma
  2. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
    Iwai Y, Ishida M, Tanaka Y, et al. · Proc Natl Acad Sci U S A · 2002 · Background
    PubMed: PMID 12218188 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung
  3. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
    Chan KY, Ozçelik H, Cheung AN, et al. · Cancer Res · 2002 · Background
    PubMed: PMID 12124354 · NCT05092412 · Lung Neoplasms

2001 (2 papers)

  1. Enhancement of tumor radioresponse by combined chemotherapy in murine hepatocarcinoma.
    Seong J, Kim SH, Suh CO, et al. · J Gastroenterol Hepatol · 2001 · Background
    PubMed: PMID 11555102 · NCT04988945 · Carcinoma, Hepatocellular
  2. Expression and function of NK cell receptors in CD8+ T cells.
    McMahon CW, Raulet DH · Curr Opin Immunol · 2001 · Background
    PubMed: PMID 11498303 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung

2000 (6 papers)

  1. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
    Young H, Baum R, Cremerius U, et al. · Eur J Cancer · 2000 · Trial result
    PubMed: PMID 10673991 · NCT03824691 (ARCADIA) · Urinary Bladder Neoplasms
  2. Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.
    Vergote I, Rustin GJ, Eisenhauer EA, et al. · J Natl Cancer Inst · 2000 · Background
    PubMed: PMID 10995813 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  3. Non-small cell lung tumors repopulate rapidly during radiation therapy.
    Fowler JF, Chappell R · Int J Radiat Oncol Biol Phys · 2000 · Background
    PubMed: PMID 10661362 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  4. Microtubule binding to Smads may regulate TGF beta activity.
    Dong C, Li Z, Alvarez R, et al. · Mol Cell · 2000 · Background
    PubMed: PMID 10678166 · NCT04696848 · Colorectal Neoplasms
  5. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress.
    Chute JP, Chen T, Feigal E, et al. · J Clin Oncol · 2000 · Background
    PubMed: PMID 10561217 · NCT03085849 · Small Cell Lung Carcinoma
  6. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
    Bubley GJ, Carducci M, Dahut W, et al. · J Clin Oncol · 2000 · Background
    PubMed: PMID 10550143 · NCT04062708 · Carcinoma, Non-Small-Cell Lung

1999 (2 papers)

  1. The ILT2(LIR1) and CD94/NKG2A NK cell receptors respectively recognize HLA-G1 and HLA-E molecules co-expressed on target cells.
    Navarro F, Llano M, Bellón T, et al. · Eur J Immunol · 1999 · Background
    PubMed: PMID 9933109 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  2. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques.
    Dautzenberg B, Arriagada R, Chammard AB, et al. · Cancer · 1999 · Background
    PubMed: PMID 10421262 · NCT04062708 · Carcinoma, Non-Small-Cell Lung

1998 (3 papers)

  1. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group.
    Lancet · 1998 · Background
    PubMed: PMID 9690404 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  2. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases.
    Le Dréan E, Vély F, Olcese L, et al. · Eur J Immunol · 1998 · Background
    PubMed: PMID 9485206 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung
  3. Small-cell lung cancer: treatment progress and prospects.
    Clark R, Ihde DC · Oncology (Williston Park) · 1998 · Background
    PubMed: PMID 9597676 · NCT05092412 · Lung Neoplasms

1996 (2 papers)

  1. The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party.
    Stephens RJ, Girling DJ, Bleehen NM, et al. · Br J Cancer · 1996 · Background
    PubMed: PMID 8761382 · NCT04062708 · Carcinoma, Non-Small-Cell Lung
  2. Postoperative radiotherapy for radically resected N2 non-small-cell lung cancer (NSCLC): randomised clinical study 1988-1992.
    Debevec M, Bitenc M, Vidmar S, et al. · Lung Cancer · 1996 · Background
    PubMed: PMID 8696724 · NCT04062708 · Carcinoma, Non-Small-Cell Lung

1995 (1 paper)

  1. Oligometastases.
    Hellman S, Weichselbaum RR · J Clin Oncol · 1995 · Background
    PubMed: PMID 7799047 · NCT03965468 (CHESS) · Carcinoma, Non-Small-Cell Lung

1992 (2 papers)

  1. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
    Roth BJ, Johnson DH, Einhorn LH, et al. · J Clin Oncol · 1992 · Background
    PubMed: PMID 1310103 · NCT05092412 · Lung Neoplasms
  2. A meta-analysis of thoracic radiotherapy for small-cell lung cancer.
    Pignon JP, Arriagada R, Ihde DC, et al. · N Engl J Med · 1992 · Background
    PubMed: PMID 1331787 · NCT05092412 · Lung Neoplasms

1989 (1 paper)

  1. Optimal two-stage designs for phase II clinical trials.
    Simon R · Control Clin Trials · 1989 · Background
    PubMed: PMID 2702835 · NCT04765709 (BRIDGE) · Carcinoma, Non-Small-Cell Lung

1985 (1 paper)

  1. VP-16 and cisplatin as first-line therapy for small-cell lung cancer.
    Evans WK, Shepherd FA, Feld R, et al. · J Clin Oncol · 1985 · Background
    PubMed: PMID 2997406 · NCT05683977 (ARSENAL) · Small Cell Lung Carcinoma

1983 (1 paper)

  1. Toxicity and response criteria of the Eastern Cooperative Oncology Group.
    Oken MM, Creech RH, Tormey DC, et al. · Am J Clin Oncol · 1983 · Background
    PubMed: PMID 7165009 · NCT05683977 (ARSENAL) · Small Cell Lung Carcinoma

1976 (1 paper)

  1. Prolonged tumor dormancy by prevention of neovascularization in the vitreous.
    Brem S, Brem H, Folkman J, et al. · Cancer Res · 1976 · Background
    PubMed: PMID 1277191 · NCT04696848 · Colorectal Neoplasms

1975 (1 paper)

  1. The randomization and stratification of patients to clinical trials.
    Zelen M · J Chronic Dis · 1975 · Background
    PubMed: PMID 4612056 · NCT07146230 (SPRINT 2) · Carcinoma, Non-Small-Cell Lung

1969 (1 paper)

  1. Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer.
    Moertel CG, Childs DS, Reitemeier RJ, et al. · Lancet · 1969 · Background
    PubMed: PMID 4186452 · NCT02311361 · Pancreatic Neoplasms

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).